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ABSTRACT: Modifications of histone tails, including ly-
sine/arginine methylation, provide the basis of a 'chromatin or 
histone code'. Proteins that contain 'reader' domains can bind to 
these modifications and form specific effector complexes, which 
ultimately mediate chromatin function. The spindlin1 (SPIN1) 
protein contains three Tudor methyllysine/arginine reader do-
mains and was identified as a putative oncogene and transcrip-
tional co-activator. Here we report a SPIN1 chemical probe inhib-
itor with low nanomolar in vitro activity, exquisite selectivity on a 
panel of methyl reader and writer proteins, and with submicromo-
lar cellular activity. X-ray crystallography showed that this Tudor 
domain chemical probe simultaneously engages Tudor domains 1 
and 2 via a bidentate binding mode. Small molecule inhibition and 
siRNA knockdown of SPIN1, as well as chemoproteomic studies, 
identified genes which are transcriptionally regulated by SPIN1 in 
squamous cell carcinoma and suggest that SPIN1 may have a roll 
in cancer related inflammation and/or cancer metastasis. 
INTRODUCTION 
Epigenetic methyllysine and arginine reader proteins play a 
crucial role in many biological processes. They bind to posttrans-
lational methylation marks on histone tails, thus interpreting and 
conveying the “histone or chromatin code” downstream.1-2 This 
large family of proteins consists of Chromo, PHD, Tudor, MBT 
and PWWP domains.3 Within the Tudor domains, there are five 
human spindlin proteins (SPIN1, 2A, 2B, 3 and 4) and each con-
tain three Tudor methyl reader domains.4-9 Spindlin1 (SPIN1) was 
initially identified in mouse oocytes,4 but has now been implicat-
ed in many cancers.7, 10-18 SPIN1 binds to trimethylated lysine 4 of 
histone 3 (H3K4me3) via the “aromatic cage” of Tudor domain 
2.17, 19-20 It can also simultaneously bind to the asymmetrically 
dimethylated arginine mark H3R8me2a via domain 1,17 which 
makes SPIN1 a bivalent methyllysine and methylarginine reader. 
SPIN1 also binds to H4K20me3 via domain 2, but little is known 
about this interaction.21 Binding to these epigenetic marks at gene 
promoter regions leads to transcriptional activation of ribosomal 
proteins20 and promotes liposarcoma, ovarian, colon, breast and 
non-small-cell lung cancers by activation of the GDNF-RET-
MAZ,7 Wnt/β-catenin,17-18 or PI3K/Akt11, 15-16 pathways respec-
tively. SPIN1 has also been shown to facilitate the inactivation of 
p53, through interaction with the ribosomal protein uL18.14 Re-
cently the C11ORF84 protein was identified that attenuates 
SPIN1 coactivator activity.22 Knockdown of SPIN1 resulted in 
cancer cell and xenograft tumor growth inhibition, which suggests 
that small molecule inhibition of SPIN1 may be a viable approach 
for the treatment of certain cancers.7, 11-15 Therefore, potent and 
selective SPIN1 inhibitors are needed to aid with the further elu-
cidation of SPIN1 biology. Micromolar inhibitors were identified 
using in silico methods23 and bidentate inhibitors that interact with 
Tudor domains 1 and 2 were reported.5   
 
 
Figure 1. Crystal structure of A-366 with G9a and SPIN1. (A) Structural of A-366 (cyan) in complex with G9a (pink) (PDB ID 
4NVQ).24 (B) Structure of A-366 (cyan) in complex with SPIN1 (PDB ID 6I8Y). 
 
However, with binding affinities above 3 µM, these inhibitors 
have considerably weaker potency than that required for chemical 
probe inhibitors (in vitro KD <100 nM).25-26 We recently identified 
a potent SPIN1 hit molecule A-366 (Figure 1, IC50 186 nM).27 
However this molecule is a potent chemical probe for the methyl-
transferase G9a (IC50 3 nM).24 Using A-366 as a starting point, we 
set out to develop SPIN1 inhibitors and we now report the bio-
chemical, structural and cellular characterization that led to a 
potent and selective SPIN1 chemical probe. 
Results 
We initially used X-ray crystallography to compare the binding 
modes of A-366 in complex with SPIN1 and G9a. Binding of A-
366 to G9a is largely dominated by polar contacts (Figure 1A).24 
While in SPIN1, interestingly, two molecules of A-366 bind, one 
in each aromatic cage of domain 1 and domain 2 (Figure 1B). In 
domain 1, binding is largely driven by π-stacking interactions 
with residues Trp62, Trp72, Tyr91, Phe94 and Tyr98, and in do-
main 2 via contacts with residues His139, Phe141, Trp151, 
Tyr177 and Tyr179, as well as, polar interactions with Asp184. 
For inhibitor design we focused on domain 2 of SPIN1, since 
binding of the H31-10K4me3-R8me2a peptide to SPIN1 is largely 
driven by the interaction of K4me3 with domain 2.17 Compared to 
G9a, domain 2 of SPIN1 can accommodate larger substituents. 
Therefore, the chemical synthesis of A-36624 was modified to 
allow incorporation of larger alkyl groups at R1 and optimized to 
allow efficient incorporation of tert-amines at R2 (Scheme 1, Se-
ries 1 & 2). 
Commercially available compound 1 was dialkylated using the 
procedure of Barbasiewicz et al, with slight modification, to in-
corporate a spirocycle (compound 2), which in later analogues, 
was replaced with gem-dimethyls (compound 3). A selective ni-
tration was achieved at low temperature, which was followed by 
debenzylation by hydrogenolysis to give the nitrophenol 6. The 
solvent mixture (9:1 EtOAc:EtOH) was decisive in determining 
the outcome of this reaction, with most other solvent mixtures 
leading to significant reduction of the nitro group. Nitrophenol 6 
was alkylated to give compound 7 and the chloride was displaced 
with pyrrolidine to give compound 8. The demethylation of 8 was 
achieved by combining aspects of the procedures reported by 
Chae et al. and Magano et al, which involved nucleophilic dis-
placement of the phenoxide by an in situ generated thiolate. De-
methylation via a lewis acid (e.g. BBr3) led to mixtures of phenols 
6 and 9. Alkylation of phenol 9 with bulkier alkylhalides was 
followed by the nitro group reduction with zinc in acetic acid. The 
resultant aniline underwent in situ ring closure to give a series of 
cyclic amidines possessing various alkyl groups at R1. For the 
preparation of series 2, the chloride of compound 7 was displaced 
with various secondary amines, followed by reductive ring clo-
sure. 
An AlphaScreen assay was employed to assess the SPIN1 bind-
ing of the compounds. Compound binding was determined by the 
displacement of a trimethylated biotinylated histone 3 peptide 
(ARTK(me3)QTARKSTGGKAPRK-biotin) from a His tagged 
SPIN1 protein using an AlphaScreen® Histidine (Nickel Chelate) 
Detection Kit. The scintillation proximity assay (SPA) reported by 
Sweis et al. was used to evaluate the G9a inhibition.24 
A methylcyclopropyl group at R1 (compound 10) imparted 
SPIN1 selectivity, while isoindolines at R2 (e.g. compound 11) 
increased the binding affinity. These optimum substituents were 
incorporated into series 3 (Scheme 1). To prepare series 3, general 
conditions (d), (e), (f), (g) and (i) were employed, but the order of 
cleavage of the benzyl- and methyl-arylethers was reversed. Se-
ries 3 contained potent SPIN1 inhibitors (Table 1, compound 22, 
23, 25). Compound 25, which had gem-dimethyls in place of a 
spirocycle, was equipotent as a SPIN1 inhibitor but showed no 
inhibition of G9a, which indicated that the spirocycle was not 
required. Compounds possessing butyl chains had dramatically 
lower potency and therefore, were used as inactive controls (Table 
1, compound 24, 26). The inactive control compound 26 had a 19-
fold decrease in potency compared to its corresponding active 
compound 25. Unexpectedly, the use of a slightly longer SPIN1 
construct resulted in a higher IC50 for A-366 (Table 1) than that 
previously reported,27 which was explored later.  
 
Scheme 1. Synthesis of SPIN1 inhibitors Series 1, 2 and 3. 
 
General conditions: (a) 1,4-dibromobutane, KOH, TBAB, PhMe, 
0 C-reflux, 3h, 92%; (b) NaOH, MeI, DMSO, rt, 1 h 98%; (c) 
HNO3, Ac2O, AcOH, -5 C, 1 h, 87-92%; (d) Pd/C, H2, 9:1 
EtOAc:EtOH, rt, 30-40 min, 76-86%; (e) alkylbromide, K2CO3, 
CH3CN, 80 C, 18 h, 92-97%; (f) 2 amine, KI, K2CO3, CH3CN, 
80 C, 48 h; (g) C12H25SH, KOtBu, DMF, 0-50 C, 2 h, 79-86%; 
(h) alkylhalide, K2CO3, DMF, 50 C, 18 h; (i) Zn, AcOH, 110 C, 
2 h, 5-82%. 
Table 1. Compound IC50 on SPIN1 (AlphaScreen assay) 
and G9a (Scintillation Proximity Assay) 
a n ≥ 2; b Sweis et al.24 
The crystal structure of compound 23 in complex with SPIN1 
(SI, Figure S1) suggested that the improved binding affinity of 
isoindoline-containing analogues may be attributed to additional 
π-stacking interactions between the isoindoline moiety and resi-
dues Phe141, Trp151, Tyr170 and Tyr177 in the aromatic cage. 
With potent compounds in hand, cellular target engagement 
was assessed using a nanoBRET assay.28 A halotag-histone 3.3 
and an N-terminal Nanoluc-SPIN1 fusion protein was overex-
pressed in U2OS cells and treated with compounds 23-26 at a 
concentration of 1 µM. A significant reduction of the nanoBRET 
signal was observed for compound 23 and 25, but not for the inac-
tive 24 and 26, which confirmed that the inhibitors indeed showed 
cellular target engagement (Figure 2). However, at elevated con-
centrations (>3 µM) increased cell death was observed (SI, Figure 
S6). Both the active and inactive compounds displayed this toxici-
ty, which implicated off-target effects. Despite significant effort, 
the toxicity issues relating to this series could not be resolved. 
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Figure 2. NanoBRET assay. Full length wild type SPIN1 and 
Histone3.3 nanobret assay showing in cell target engagement 
for compound 23 and 25. Graph shows fold change in milli-
BRET Units (mBU) after 24h treatment with compounds at 
1M. Mean±SD, n=3 independent experiments, n≥3 internal 
replicates. One way ANOVA with Dunnetts post-hoc multiple 
comparison test, ** p<0.005. 
Recently bidentate inhibitors were reported that engaged both 
domain 1 and 2 of SPIN1, and although they had weak affinity, 
they showed a good degree of selectivity.5 Therefore, in efforts to 
increase the SPIN1 selectivity and binding affinity, and to over-
come the toxicity issues, bidentate inhibitors were designed. We 
aimed to link compound 25 to the moiety report by Bae et al.5 
which binds to domain 1 of SPIN1 (Scheme 2, highlighted in 
blue). The initial use of simple alkyl chain linkers resulted in 
highly flexible molecules, which did not engage with two SPIN1 
domains. Therefore, the Huisgen copper catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction was utilized since it resulted in 
more rigid and hydrophilic triazole-containing linkers. It also 
allowed the linker length to be varied easily. Alkyne-
functionalized isoindolines 27 and 28 (Scheme 2) were prepared 
by O-alkylation of the corresponding N-Boc protected phenol, 
followed by Boc deprotection. Alkylation at the 5-position of 
these isoindolines was chosen, since earlier structure-activity 
relationship studies revealed that substitution at this position was 
well tolerated (e.g. Scheme 1, compound 22). Using general con-
ditions (f), isoindoline 27 and 28 were coupled to 19 and 21 to 
give compounds 29-31, which were subjected to the CuAAC reac-
tion (general conditions (j)) with azide-functionalized 32 and 33, 
using copper powder as catalyst (Scheme 2). Reductive cycliza-
tion using general conditions (i) afforded compounds 34-38. Az-
ide-functionalized 32 and 33 were prepared by amide coupling of 
commercially available 4-(2-(Pyrrolidin-1-yl)ethyl)piperidine 
with the corresponding azido carboxylic acids. The bidentate 
compounds 34-38, as well as compound 25, were evaluated as 
SPIN1 inhibitors using a range of biophysical assays (Table 2). 
Three of these compounds displayed a large increase in potency 
compared to 25. Compound 35 was chosen as a chemical probe 
candidate since it displayed marginally better results in three of 
the four assays. Based on the isothermal titration calorimetry 
(ITC) alone, there was little to distinguish between compounds 
35-37.   
Compound 
SPIN149-262 IC50  
[µM] 
(hill slope, SD) 
G9a IC50  
[µM] (hill slope) 
10 1.12 (1.0, 0.30) 3.1 (0.8) 
11 0.66 (0.8, 0.46) 10 (0.7) 
22 0.34 (1.0, 0.21) Not determined 
23 0.39 (1.0, 0.25) No inhibition 
24 6.22 (0.8, 3.20) No inhibition 
25 0.36 (0.8, 0.06) No inhibition 
26 6.92 (0.7, 0.88) No inhibition 
A-366 1.5 0.003 b 
 
Scheme 2. Synthesis of bidentate SPIN1 inhibitors. 
 
General conditions: (f) 2 amine, KI, K2CO3, CH3CN, 80 C, 48 
h; (j) Cu, DMF, 60 C, 2 h; (i) Zn, AcOH, 110 C, 2 h, 5-82%. 
Table 2. Biophysical assays of bidentate SPIN1 inhibitors. 
Cmp 
AlphaScreen 
SPIN126-262 IC50 [nM] 










25 362 (0.8, 0.06) 94 15.4 6.8±0 
34 152 (1.4, 0.12) 400 60 nd 
35 33 (2.3, 0.01) 55 9.9 13.2±0.3 
36 48 (1.4, 0.03) 67 6.6 12.8±0.2 
37 59 (1.8, 0.04) 72 10.1 11.0±0 
38 3388 (0.7, 1.24) nd 1300 1.0±0 
an ≥ 2. Abbreviations; BLI (BioLayer Interferometry), ITC (Isothermal Titration 
Calorimetry), nd (not determined). 
It is worth noting that compound 35 is considerably more po-
tent as a SPIN1 inhibitor than those reported previously.5 
Compound 38 was prepared as an inactive control. ITC showed 
that 38 was approx. 130 times less potent than 35 and thus, com-
pounds 35 and 38 represent good candidates for an active and 
inactive chemical probe pairing (CPP). 
The crystal structure of 35 in complex with SPIN1 confirmed a 
bidentate binding mode, where the ethylpyrrolidine moiety indeed 
occupies the aromatic cage of domain 1, while binding of the 
isoindoline to domain 2 is retained (Figure 3).  
Figure 4. Human Tudor Domain Phylogenetic tree with SPIN 
subfamily highlighted. 









35 9.9 111.1 46.1 131.1 18.1 
There are 5 distinct human SPIN family members which form a 
distinct branch of the Tudor domain phylogenetic tree (Figure 
4).The selectivity of 35 was assessed by ITC on four SPIN sub-
family members (Table 3). SPIN2A was omitted due to its simi-
larity to SPIN2B and its low endogenous expression. The results 
showed that compound 35 binds with varying affinity across the 
subfamily (KD 10-130 nM). This suggests a similar binding mode 
among the SPIN proteins and is in line with their overall struc-
tures and peptide binding features (SI, Figure S2). 
 
Figure 3. Crystal structure of SPIN149-262 in complex with compound 35 (PDB ID 6I8B). Left, electrostatic surface potential of 
SPIN1 with 35. Right, interactions of 35 (cyan) with SPIN1 (domains 1, 2 & 3 are shown in magenta, green & yellow respectively). 
  
 
In order to investigate the discrepancies between the SPIN1 
IC50 of A-366 observed here (Table 1) versus that reported previ-
ously,27 the ITC of compound 35 was performed using two SPIN1 
constructs (Table 3). SPIN126-262 was used here in the AlphaS-
creen assay, while SPIN149-262 was employed in the previous 
study.27 The use of a SPIN1 construct ranging from residues 49-
262 resulted in a 10- to 15-fold lower KD compared to that ob-
tained with the longer construct of residues 26-262, which is in 
agreement with the previous study. 
Further investigation into the influence of the protein construct 
on ligand binding was deemed unnecessary, since the nanoBRET 
cellular target engagement assay employed here, used full length 
SPIN1. Compound 35 displayed potent cellular SPIN1 inhibition 
(Figure 5) and with an EC50 of 270 nM, it has cellular potency 
well within the acceptable range for a chemical probe.25-26 The 
inactive control compound 38 displayed no inhibition and crucial-
ly, nonspecific toxicity was not observed for 35 or 38.  
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Figure 5. NanoBRET assay results for compound 35 and 38 
using full length wild-type SPIN1 & Histone 3.3. Graph shows 
milliBRET Units (mBU) after 24h treatment with 0.05-15 µM 
of compound 35 and 38. 
Compound 35 and 38 were screened against methyl-Lys/Arg 
binding domains (including Chromo, PHD, Tudor and MBT do-
mains) using a SYPRO Orange thermal shift assay (DSF (Differ-
ential Scanning Fluorimetry)).29 In agreement with the ITC data, 
compound 35 induced a large shift in the thermal stability of all 
SPIN proteins assessed (ΔTm 6.5-14.1 °C, Figure 6). No other 
significant thermal shift was observed for compound 35 or 38. 
Compound 35 and 38 were also tested against 33 protein, DNA 
or RNA methyltransferases using established enzymatic SPAs as 
described previously.30 The compounds were initially tested at 
high concentration (10 and 50 µM, Figure 6) and where inhibition 
occurred,  
 
Figure 6. (LEFT) Heatmap of selected methyl-Lys/Arg reader 
domains using DSF (thermal shift assay). Scale shows ΔT C. 
(RIGHT) Percentage enzyme activity of 33 methyltransferases 
after compound treatment at 10 and 50 µM. 
IC50 values were determined (SI, Table S4). Compound 35 dis-
played at least 300-fold selectivity over all methyltransferases 
tested. 
In addition, a fluorescence polarization assay was employed to 
test compound 35 and 38 against the malignant brain tumor me-
thyl readers, L3MBTL1 and L3MBTL3. The compounds showed 
no significant inhibition and compound 35 had approximately 
250-fold higher potency towards SPIN1 than towards these MBT 
methyl readers (SI, Figure S5). 
Chemoproteomics was employed to identify cellular interacting 
partners of compound 35.31 Compound 41 was prepared by sub-
jecting isoindoline 39 and chloride 19 to general conditions (f) 
and (i) to give the benzyl protected 40. Hydrogenolysis, followed 
by alkylation with 4-(Boc-amino)butyl bromide, and Boc depro-
tection, gave the amino functionalized 41 (Scheme 3). The affinity 
probe 41 was coupled to NHS-activated sepharose beads and in-
cubated with SCC040 cell lysates in the presence of compound 35 
or 38. Label-free quantification (LFQ) protein mass spectrometry 
was used to identify compound-specific interactors. The SCC040 
head and neck squamous cell carcinoma (HNSCC) cell line was 
chosen since SPIN1 expression in squamous cell carcinoma tu-
mors was strongly correlated to smooth muscle actin and galectin-
1, which may contribute to cell invasion and proliferation.32 
Scheme 3. Synthesis of affinity probe 41. 
 
Conditions: general conditions (f) 2 amine, KI, K2CO3, CH3CN, 
80 C, 48 h; general conditions (i) Zn, AcOH, 110 C, 2 h, 63% 
over 2 steps; (k) Pd/C, H2, MeOH, rt, 18 h; 4-(Boc-amino)butyl 
bromide, K2CO3, DMF, rt, 48 h; TFA, DCM, rt, 2h, 12% overall.   
 
Gratifyingly, the only interacting partners of 35 were SPIN1, 
SPIN4 and the C11ORF84 (SPIN.DOC) protein (Figure 7, SI 
data.xls). The recent report by Bae et al. found that SPIN.DOC 
interacts with SPIN1 (as well as the other SPIN proteins) to mask 
Tudor domain 2 and impede its ability to bind to H3K4me3.22 
However, our results indicate that the SPIN1 domain 2 is not im-
peded by the presence of SPIN.DOC, since both proteins were 
pulled down by the affinity probe 41, which interacts with Tudor 
domain 2. It is possible that the affinity probe 41 can bind to, and 
pull down, SPIN.DOC directly. However, since SPIN.DOC was 
shown to bind directly to all SPIN proteins,22 it is more likely that 
the affinity probe 41 can pulldown SPIN.DOC as a complex with 
the SPINs, and that compound 35 competes only with the interac-
tion of SPIN1, or SPIN4, and the affinity probe. The results here 
seems to indicate that the interaction site of SPIN.DOC with the 
SPIN proteins is independent of Tudor domain 2, and therefore, 
further investigation is required. 
 
Figure 7. Chemoproteomic analyses using compound 35 
(Top) or 38 (Bottom) as competitors in human squamous car-
cinoma cell line SCC040 lysates. 
Taken together, all the selectivity data demonstrates that com-
pound 35 has excellent in vitro specificity, including in a cellular 
context. 
The proliferation, cell cycle and apoptosis of SCC040 cells was 
assessed following treatment with compound 35 and 38, (Figure 
S7). A moderate decrease in proliferation and increase in apopto-
sis was observed for compound 35, but not 38. Although this re-
sponse was significant, it was not as dramatic as we expected. 
Therefore, to gain a greater understanding of role of SPIN1 in 
SCC040 cells, RNAseq analysis was performed (Figure S8-S11, 
SI data.xls). RNA was isolated after treatment with compound 35 
or 38 (1 µM for 5 or 7 days), or with SPIN1 specific siRNA (2 or 
4 days).7 Analysis of the induced changes identified 50 genes that 
were modulated by both compound 35 and the siRNA (Figure 8, 
SI data.xls). The overlap of genes modulated by compound 35 and 
38 was minimal, which indicates that the transcriptional signature 
induced by compound 35 can be attributed to on-target effects. 
When the transcriptional modulation induced by compound 35 
is compared to that of siRNA SPIN1 knockdown, in many cases 
the genes appear to be modulated in opposing directions. Howev-
er, since several genes were upregulated at the first timepoint, but 
were downregulated at the second (S100A8, S100A9, CLDN8, 
SLPI, S100P), it is clear that the transcriptional modulation is a 
dynamic process, and therefore, at a given timepoint the siRNA 
knockdown data may not be comparable to the compound inhibi-
tion data at that timepoint.  
The identification of 6 members of the serine protease inhibitor 
superfamily (SERPINB4, SERPINB3, SERPINB13, SLPI, 
SPINK5, PI3)33-40 and 3 members of the S100 proteins (S100P, 
S100A8, S100A9),36, 41-45 as well as, a chemokine (CCL5) and an 
immune checkpoint inhibitor (NT5E (CD73)), suggests that 
SPIN1 may have a role in the activation of inflammatory respons-
es. The recent report by Bae et al. showed that treatment with the 
weak SPIN1 inhibitor EML631 (KD 4 µM) resulted in the de-
creased expression of the pro-inflammatory cytokine IL1β,46 as 
well as, BST2, which has been shown to activate the NF-κB in-
flammatory pathway in nasopharyngeal cancer.47 Inflammation 
within the tumor microenvironment (cancer-related inflammation 
(CRI)) is now known to be a significant contributing factor in the 
development and progression of cancer, particularly in tumor 
invasion and metastasis.44, 48 
Of the 50 genes identified here, a number have previously been 
reported to be differentially expressed (GBP2,49 DUOX2,50 
IGFBP351-52), or were associated with a more invasive and meta-
static phenotype (AKR1B10,53 FABP5,53-54 HSPB1,53 KRT1,53 
S100A9,53 CNFN,55 ID2,56 LCN2 (NGAL),57 IGFBP2,52 IFIT1,58 
CCL548, 59-60) in squamous cell carcinomas (SCC).  
 
Figure 8. Heatmap of overlapping genes modulated by com-
pound 35 and siRNA knockdown in SCC040 cells. 
Importantly, compound 35 seems to modulate these genes in a 
direction which opposes that identified in these previously report-
ed studies, thus may be of therapeutic value. 
 
In order to aid with the further development of compound 35 as 
a potential in vivo candidate, the in vitro permeability, stability 
and aqueous solubility were assessed. The intrinsic clearance, 
half-life and permeability were all within acceptable ranges, and 
the compound showed no efflux (Table 4). Compound 35 is high-
ly soluble, with an aqueous solubility of >100 µM (SI, Table 
S11). Therefore, despite its large molecular weight, compound 35 
is suitable for further development. 
Table 4. In vitro permeability and stability of compound 
35 performed by Cyprotex Ltd. 

















a Human. b Mouse 
DISCUSSION AND CONCLUSIONS 
We have developed a first-in-class potent, selective and cell-
active chemical probe of the SPIN subfamily of Tudor domains. 
The selectivity of compound 35 and 38 has been extensively char-
acterized and the value of this CPP as a tool to study the biology 
of SPIN proteins was demonstrated by analysis of the induced 
transcriptional changes. This analysis highlighted a significant 
number of genes that have previously been reported to be associ-
ated with CRI and/or cancer metastasis. Taken together, this data 
seems to suggest that SPIN1 may play a role in CRI and/or the 
metastatic potential of tumors, and warrants further investigation. 
The availability of a potent and cell active inhibitor, as well as, an 
inactive control compound, will facilitate and expedite the future 
evaluation of SPIN1. For future work we have named compound 
35 VinSpinIn (Vinnie’s Spindlin Inhibitor) and 38 VinSpinIC 
(Vinnie’s Spindlin Inactive Control). For a limited period, this 
CPP, along with other highly characterized chemical probes, are 
freely available to the scientific community via online request 
from https://www.thesgc.org/chemical-probes. 
EXPERIMENTAL SECTION 
Chemistry General Materials and Methods 
All solvents and reagents were purchased from commercial 
sources and used without further purification. Chemical reactions 
were carried out in anhydrous solvents, which were purchased 
from Acros Organics. Thin Layer Chromatography (TLC) was 
carried out using aluminum plates coated with 60 F254 silica gel 
and were visualized using UV light (254 or 365 nm) unless oth-
erwise stated. Automated flash chromatography was carried out 
on a Biotage Isolera One flash column chromatography system 
(LPLC), using Biotage® SNAP KP-Sil cartridges (unless other-
wise state). All end compounds were purified to ≥95% purity, as 
indicated by analytical reverse phase high performance liquid 
chromatography (RP-HPLC) using UV and ELSD detection, as 
well as, 1H NMR and 13C NMR. Analytical HPLC and low resolu-
tion mass spectrometry was carried out on a waters LCMS system 
(Waters 2767 Sample Manager, Waters SFO System Fluidics 
Organizer, Waters 2545 Binary Gradient Module, 2 x Waters 515 
HPLC pumps, Waters 2998 Photodiode Array Detector, Waters 
2424 ELS Detector, Waters SQ Detector 2). Analytical separation 
was carried out on a Kinetex 5 μM EVO C18 column (100 mm × 
3.0 mm, 100 A) using a flow rate of 2 mL/min in a 3 min gradient 
elution. The mobile phase was a mixture of 93% water, 5% ace-
tonitrile, and 2% of 0.5 M ammonium acetate adjusted to pH 6 
with glacial acetic acid (solvent A) and 18% water, 80% acetoni-
trile, and 2% of 0.5 M ammonium acetate adjusted to pH 6 with 
glacial acetic acid (solvent B). Gradient elution was as follows: 
95:5 (A/B) 0.35 min, 95:5 (A/B) to 5:95 (A/B) over 1 min, 5:95 
(A/B) over 0.75 min, and then reversion back to 95:5 (A/B) over 
0.1 min and 95:5 (A/B) over 0.8 min.  
NMR spectra were recorded using a Bruker Avance 400 MHz 
spectrometer using the indicated deuterated solvent. Chemical 
shifts (δ) are quoted in parts per million (ppm) and referenced to 
the residual solvent peak. Multiplicities are denoted as s- singlet, 
d- doublet, t- triplet and q- quartet, and derivatives thereof. Cou-
pling constants are recorded in Hz and rounded to the nearest 0.1 
Hz. Two-dimensional NMR experiments (COSY, HSQC) were 
used to aid the assignment of 1H and 13C spectra. Atom number-
ing in structures is purely for the purposes of assignment and does 
not reflect any numbering conventions. 
All end compounds were examined to confirm that they did not 
contain known classes of pan-assay interference motifs. 
Conditions (a); Synthesis of 1-(4-(benzyloxy)-3-
methoxyphenyl)cyclopentane-1-carbonitrile (2); The procedure 
of Barbasiewicz et al. was used with slight modification.61 Potas-
sium hydroxide (8.44 g, 150 mmol, 12 eq) and water (2.8 mL) 
were added to a stirring solution of 2-(4-(benzyloxy)-3-
methoxyphenyl)acetonitrile 1 (3.17 g, 12.51 mmol, 1 eq) and 1,4-
dibromobutane (2.99 mL, 25.03 mmol, 2.0 eq) in toluene (100 
mL). The mixture was cooled to 0 °C and tetrabutylammonium 
bromide (60.5 mg, 0.188 mmol, 0.015 eq) was added. The mix-
ture was stirred at 0 °C for approx. 15 min, then heated to 80 °C 
with slow stirring (50 rpm) until most of the KOH had dissolved 
(approx. 1 h). The mixture was heated at reflux and stirred vigor-
ously for a further 2 h. Water (75 mL) was added to the cooled 
reaction mixture. The organic phase was separated, washed with 
water (3 x 50 mL), dried (Na2SO4), evaporated and the residue 
was purified by chromatography using a gradient of 0-40% of [1:1 
DCM:EtOAc] in cyclohexane to give compound 2 (3.545 g, 11.53 
mmol, 92%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.23-
7.16 (m, 4H), 6.82 (s, 2H), 4.13 (t, J = 6.3 Hz, 2H), 3.96 (s, 4H), 
3.81 (d, J = 6.9 Hz, 2H), 2.94 (t, J = 7.4 Hz, 2H), 2.16-1.88 (m, 
10H), 1.32-1.22 (m, 1H), 0.62-0.56 (m, 2H), 0.35-0.30 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 149.74, 147.76, 136.95, 132.76 (4 
x C), 128.59, 127.91, 127.23 (3 x CH), 124.58 (C), 118.03, 
113.89, 110.28 (3 x CH), 71.06 (CH2), 56.18 (CH3), 47.39 (C), 
40.37, 24.11 (2 x CH2). HPLC: tR 1.80 min. MS (ESI+): m/z 
325.2 [M+NH4]+. 
Conditions (b); Synthesis of 2-(4-(benzyloxy)-3-
methoxyphenyl)-2-methylpropanenitrile (3); A solution of the 
2-(4-(benzyloxy)-3-methoxyphenyl)acetonitrile 1 (1.387 g, 5.48 
mmol, 1 eq) and sodium hydroxide (aq. 50 wt%, 1.752 g, 21.90 
mmol, 4 eq) in DMSO (10 mL) were cooled to 0 °C. Iodomethane 
(1.36 ml, 21.90 mmol, 4 eq) was added dropwise and the mixture 
was stirred at room temperature for 1 h after the addition. The 
mixture was diluted with water (100 mL) and the product was 
extracted with toluene (3 x 30 mL), dried (Na2SO4) and evapo-
rated to give compound 3 (1.508 g, 5.36 mmol, 98%) as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.45-7.42 (m, 2H), 7.40-7.34 
(m, 2H), 7.33-7.29 (m, 1H), 7.00 (d, J = 2.2 Hz, 1H), 6.92 (dd, J = 
8.4, 2.2 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 5.15 (s, 2H), 3.92 (s, 
3H), 1.70 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 149.76, 147.73, 
136.93, 134.49 (4 x C), 128.59, 127.92, 127.24 (3 x CH), 124.71 
(C), 117.07, 113.94, 109.43 (3 x CH), 71.06 (CH2), 56.19 (CH3), 
36.76 (C), 29.25 (CH3). HPLC: tR 1.80 min. MS (ESI+): m/z 
299.6 [M+NH4]+. 
General conditions (c); The procedure of Sweis et al. was 
used with slight modification.24 A solution of 2 or 3 (7.0 mmol, 1 
eq), in 1:1 acetic acid:acetic anhydride (5 mL), was added drop-
wise to a solution of glacial acetic acid (5 mL), acetic anhydride 
(5 mL) and nitric acid (70%, 5 mL), maintaining the internal tem-
perature of the reaction between 0 and -5°C. The mixture was 
 
stirred at 0 °C for approx. 30 min after the addition. The reaction 
mixture was poured over crushed ice and stirred vigorously for 
approx. 10 mins. The product was isolated by filtration and rinsed 
thoroughly with cold water. 
1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)cyclopentane-1-
carbonitrile (4); Prepared using general conditions (c) from 
compound 2. (95%) pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 7.50 (s, 1H), 7.45-7.32 (m, 5H), 6.99 (s, 1H), 5.18 (s, 
2H), 3.97 (s, 3H), 2.75-2.64 (m, 2H), 2.10-1.98 (m, 4H), 1.98-
1.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 152.62, 147.46, 
142.50, 135.38 (4 x C), 128.83, 128.53, 127.54 (3 x CH), 127.49, 
122.81 (2 x C), 111.15, 110.92 (2 x CH), 71.37 (CH2), 56.47 
(CH3), 45.43 (C), 38.95, 23.84 (2 x CH2). HPLC: tR 1.87 min. MS 
(ESI+): m/z 370.6 [M+NH4]+. 
2-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)-2-
methylpropanenitrile (5); Prepared using general conditions (c) 
from compound 3. (87%) pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 7.45-7.31 (m, 6H), 7.06 (s, 1H), 5.17 (s, 2H), 3.98 (s, 
3H), 1.89 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 152.54, 147.40, 
142.23, 135.36 (4 x C), 128.82, 128.52 (2 x CH), 127.77 (C), 
127.53 (CH), 123.00 (C), 111.08, 110.19 (2 x CH), 71.39 (CH2), 
56.47 (CH3), 36.44 (C), 28.36 (CH3). HPLC: tR 1.71 min. MS 
(ESI+): m/z 327.2 [M+H]+. 
General Conditions (d); Palladium (10% on carbon (50% 
wet), 0.2 weight eq) was added to a solution of Benzyl aryl ether 
4, 14 or 15 (2.0 mmol, 1 eq) in 9:1 EtOAc:EtOH (50 mL). The 
system was flushed with N2, followed by H2 and the mixture was 
stirred at room temperature under H2. The reaction was monitored 
closely by TLC and was complete in approximately 30 min. The 
catalyst was removed by filtration through a bed of celite® and 
the solvent was evaporated. The residue was purified by automat-
ed flash chromatography using a gradient elution of 0-10% MeOH 
in DCM. 
1-(4-hydroxy-5-methoxy-2-nitrophenyl)cyclopentane-1-
carbonitrile (6); Prepared using general conditions (d) from ben-
zyl aryl ether 4. (84%) pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.46 (s, 1H), 6.96 (s, 1H), 5.86 (bs, 1H), 4.00 (s, 3H), 
2.74-2.63 (m, 2H), 2.10-1.96 (m, 4H), 1.96-1.82 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 149.34, 145.26, 143.38, 126.20, 
122.88 (5 x C), 112.56, 109.99 (2 x CH), 56.44 (CH3), 45.38 (C), 
38.95, 23.80 (2 x CH2). HPLC: tR 1.41 min. MS (ESI+): m/z 
263.2 [M+H]+. 
General conditions (e); Phenol 6, 12, 13, 16 or 17 (3.0 mmol, 
1 eq), potassium carbonate (2 eq) and the required alkyl bromide 
(1.5 eq) (1-bromo-3-chloropropane for 7, 18, 19; (bromome-
thyl)cyclopropane for 14, 15; 1-bromo-4-chlorobutane for 20, 21) 
were heated in ACN (20 mL) at 80 °C overnight. The cooled reac-
tion mixture was evaporated and the residue was purified by au-
tomated flash chromatography using a gradient elution of 50-
100% DCM in cyclohexane. 
1-(4-(3-chloropropoxy)-5-methoxy-2-
nitrophenyl)cyclopentane-1-carbonitrile (7); Prepared using 
general conditions (e) from phenol 6. (97%) yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 7.00 (s, 1H), 4.24 (t, J = 
5.9 Hz, 2H), 3.97 (s, 3H), 3.78 (t, J = 6.2 Hz, 2H), 2.77-2.66 (m, 
2H), 2.36-2.28 (m, 2H), 2.12-1.98 (m, 4H), 1.98-1.84 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 150.52, 145.67, 140.67, 125.56, 
120.87 (5 x C), 108.95, 108.68 (2 x C), 64.03 (CH2), 54.49 (CH3), 
43.49 (C), 39.21, 37.04, 29.92, 21.92 (4 x CH2). HPLC: tR 1.73 
min. MS (ESI+): m/z 339.2 [M+H]+. 
General conditions (f); Alkyl chloride 7 or 18-21 (0.25 mmol, 
1 eq), potassium iodide (2 eq), potassium carbonate (3 eq) and the 
required secondary amine (1.5 eq) were heated in ACN at 80 °C 
(5 mL) for 48 h. The cooled reaction mixture was evaporated and 
the residue was purified by automated flash chromatography us-
ing a gradient elution of 0-5% MeOH in DCM.  
1-(5-methoxy-2-nitro-4-(3-(pyrrolidin-1-
yl)propoxy)phenyl)cyclopentane-1-carbonitrile (8); Prepared 
using general conditions (f) from alkyl chloride 7. (91%) yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 6.96 (s, 1H), 4.15 
(t, J = 6.6 Hz, 2H), 3.95 (s, 3H), 2.75-2.65 (m, 2H), 2.62 (t, J = 
7.2 Hz, 2H), 2.55-2.48 (m, 4H), 2.10-1.97 (m, 6H), 1.97-1.83 (m, 
2H), 1.83-1.74 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 152.30, 
148.00, 142.69, 126.89, 122.87 (5 x C), 110.82, 110.39 (2 x CH), 
68.03 (CH2), 56.45 (CH3), 54.22, 52.65 (2 x CH2), 45.39 (C), 
38.94, 28.44, 23.83, 23.48 (4 x CH2). HPLC: tR 1.33 min. MS 
(ESI+): m/z 374.4 [M+H]+. 
General conditions (g); Aspects of the procedures of Chae et 
al. and Magano et al. were used with modifications.62-63 Dodec-
ane-1-thiol (2.4 eq) was added to a solution of potassium tert-
butoxide (2.5 eq) in dry DMF (40 mL) under N2, which resulted 
in a heavy white precipitate. The mixture was cooled in an ice 
bath and a solution of methyl aryl ether 4, 5 or 8 (5.0 mmol, 1 eq) 
in dry DMF (20 mL) was added dropwise maintaining the tem-
perature at 0 °C. After the addition, the mixture was heated to 50 
°C for approx. 2 hours and monitored by TLC. Solid sodium hy-
drogen sulfate (4 eq) was added to the cooled reaction and the 
mixture was stirred vigorously until a color change, from orange 
to pale yellow, occurred. The solvent was evaporated and the 
residue was purified by automated flash chromatography using a 
gradient elution of 50-100% DCM in cyclohexane as eluent. 
1-(5-hydroxy-2-nitro-4-(3-(pyrrolidin-1-
yl)propoxy)phenyl)cyclopentane-1-carbonitrile (9); Prepared 
using general conditions (g) from methyl aryl ether 8, but was 
purified using a Biotage® SNAP KP-NH column, with a gradient 
elution of 0-10% MeOH in DCM. (88%) yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.78 (s, 1H), 6.81 (s,1H), 4.01 (t, J = 5.0 Hz, 
2H), 3.10-2.98 (m, 6H), 2.70-2.58 (m, 2H), 2.11-1.89 (m, 10 H), 
1.89-1.74 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 163.33, 
146.70, 135.96, 133.40, 123.53 (5 x C), 120.68, 118.32 (2 x CH), 
72.75, 54.55, 53.79 (3 x CH2), 45.55 (C), 38.88, 26.65, 23.77, 
23.21 (4 x CH2). HPLC: tR 1.25 min. MS (ESI+): m/z 360.3 
[M+H]+. 
Conditions (h); Phenol 9 (0.25 mmol, 1 eq), potassium car-
bonate (2 eq) and (Bromomethyl)cyclopropane (1.5 eq) were 
heated in DMF (5 mL) at 50 °C overnight. The cooled reaction 
mixture was evaporated and the residue was purified by automat-
ed flash chromatography using a gradient elution of 0-5% MeOH 
in DCM. The product was immediately subjected to general con-
ditions (i). 
General conditions (i); The procedure of Sweis et al. was used 
with modifications.24 Zinc powder (10 eq) was added to the ni-
troarene (0.25 mmol, 1 eq) and the mixture was stirred vigorously 
in glacial acetic acid (5 mL) at 110 °C for 2 h. The acetic acid was 
evaporated and the residue was dissolved in DCM (2 mL). Solid 
potassium carbonate (10 eq) was added and the mixture was 
stirred vigorously until CO2 was no longer liberated. The mixture 
was directly loaded onto a Biotage® SNAP KP-NH column and 
the product was eluted with an eluent of 0-10% MeOH in DCM. 
5'-(cyclopropylmethoxy)-6'-(3-(pyrrolidin-1-
yl)propoxy)spiro[cyclopentane-1,3'-indol]-2'-amine (10); Pre-
pared using general conditions (h) and (i) from phenol 9. (6%) 
colorless oil that solidifies on standing. 1H NMR (400 MHz, 
CDCl3) δ 6.81 (s, 1H), 6.79 (s, 1H), 4.05 (t, J = 6.4 Hz, 2H), 3.79 
(d, J = 7.0 Hz, 2H), 2.64 (t, J = 7.6, 2H), 2.55-2.47 (m, 2H), 2.10-
1.88 (m, 10H), 1.83-1.72 (m, 4H), 1.31-1.19 (m, 1H), 0.61-0.54 
(m, 2H), 0.33-0.27 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
179.50, 150.08, 149.18, 144.05, 135.05 (5 x C), 112.13, 103.44 (2 
x CH), 76.68, 67.81 (2 x CH2), 58.62 (C), 54.30, 53.36, 38.10, 
 
29.06, 26.61, 23.48 (6 x CH2), 10.86 (C), 3.13 (CH2). HPLC: 
100%, tR 1.13 min. MS (ESI+): m/z 384.5 [M+H]+. 
6'-(3-(isoindolin-2-yl)propoxy)-5'-
methoxyspiro[cyclopentane-1,3'-indol]-2'-amine (11); Prepared 
using general conditions (f) and (i) from alkyl chloride 7. (29%) 
colorless oil that solidifies on standing. 1H NMR (400 MHz, 
CDCl3) δ 7.22-7.14 (m, 5H), 6.84 (s, 1H), 6.77 (s, 1H), 4.15 (t, J 
= 6.6 Hz, 2H), 3.95 (s, 4H), 3.85 (s, 3H), 2.93 (t, J = 7.3 Hz, 2H), 
2.17-1.90 (m, 10H). 13C NMR (101 MHz, CDCl3) δ 179.30, 
148.76, 148.25, 145.11, 140.17, 134.90 (6 x C), 126.64, 122.26, 
107.72, 103.30 (4 x CH), 67.61, 59.20 (CH2), 58.78 (C), 57.68 
(CH3), 52.90, 38.08, 28.87, 26.69 (CH2). HPLC: 96%, tR 1.19 
min. MS (ESI+): m/z 392.4 [M+H]+. 
1-(4-(benzyloxy)-5-hydroxy-2-nitrophenyl)cyclopentane-1-
carbonitrile (12); Prepared using general conditions (g) from 
methyl aryl ether 4. (86%) yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.59 (s, 1H), 7.47-7.38 (m, 5H), 7.09 (s, 1H), 6.09 (s, 
1H), 5.18 (s, 2H), 2.73-2.63 (m, 2H), 2.09-1.97 (m, 4H), 1.94-
1.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 149.53, 144.63, 
142.14, 134.57 (4 x C), 129.11, 129.01 (2 x CH), 128.72 (C), 
128.16 (CH), 122.66 (C), 114.47, 110.30 (2 x CH), 71.88 (CH2), 
44.97 (C), 39.03, 23.75 (2 x CH2). HPLC: 98%, tR 1.64 min. MS 
(ESI+): m/z 339.3 [M+H]+. 
2-(4-(benzyloxy)-5-hydroxy-2-nitrophenyl)-2-
methylpropanenitrile (13); Prepared using general conditions (g) 
from methyl aryl ether 5. (79%) yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.51 (s, 1H), 7.47-7.36 (m, 5H), 7.12 (s, 1H), 5.17 (s, 
2H), 1.87 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 149.61, 144.65, 
141.89, 134.61, 129.24 (5 x C), 129.11, 129.01, 128.17 (3 x CH), 
122.60 (C), 113.50, 110.28 (2 x CH), 71.87 (CH2), 35.43 (C), 
28.83 (CH3) HPLC: tR 1.63 min. MS (ESI+): m/z 330.6 
[M+NH4]+. 
1-(4-(benzyloxy)-5-(cyclopropylmethoxy)-2-
nitrophenyl)cyclopentane-1-carbonitrile (14); Prepared using 
general conditions (e) from phenol 12. (99%) yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 7.51 (s, 1H),7.46-7.32 (m, 5H), 6.99 
(s, 1H), 5.19 (s, 2H), 3.97 (d, J = 6.9 Hz, 2H), 2.73-2.61 (m, 2H), 
2.10-1.96 (m, 4H), 1.96-1.81 (m, 2H), 1.37-1.23 (m, 1H), 0.71-
0.67 (m, 2H), 0.42-0.38 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
152.38, 147.88, 142.54, 135.72 (4 x C), 128.75, 128.37 (2 x CH), 
127.56 (C), 127.34 (CH), 122.85 (C), 113.23, 112.04 (2 x CH), 
74.57, 71.45 (2 x CH), 45.36 (C), 38.94, 23.83 (2 x CH2), 10.14 
(CH3), 3.48 (CH2). HPLC: tR 2.03 min. MS (ESI+): m/z 410.7 
[M+NH4]+. 
2-(4-(benzyloxy)-5-(cyclopropylmethoxy)-2-nitrophenyl)-2-
methylpropanenitrile (15); Prepared using general conditions (e) 
from phenol 13. (92%) yellow solid. 1H NMR (400 MHz, CDCl3) 
δ 7.46-7.31 (m, 6H), 7.07 (s, 1H), 5.18 (s, 2H), 3.98 (d, J = 6.9 
Hz, 2H), 1.87 (s, 6H), 1.37-1.28 (m, 1H), 0.71-0.66 (m, 2H), 0.42-
0.378 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 152.30, 147.81, 
142.26, 135.71 (4 x C), 128.73, 128.36 (2 x CH), 127.86 (C), 
127.33 (CH), 123.04 (C), 112.46, 111.98 (2 x CH), 74.55, 71.47 
(2 x CH2), 36.34 (C), 28.39 (CH3), 10.12 (CH), 3.46 (CH2). 
HPLC: tR 1.84 min. MS (ESI+): m/z 367.4 [M+H]+. 
1-(5-(cyclopropylmethoxy)-4-hydroxy-2-
nitrophenyl)cyclopentane-1-carbonitrile (16); Prepared using 
general conditions (d) from benzyl aryl ether 14. (76%) pale yel-
low oil. 1H NMR (400 MHz, CDCl3) δ 7.47 (s, 1H), 6.92 (s, 1H), 
3.96 (d, J = 7.2 Hz, 2H), 2.72-2.59 (m, 2H), 2.09-1.94 (m, 4H), 
1.94-1.81 (m, 2H), 1.36-1.24 (m, 1H), 0.76-0.68 (m, 2H), 0.43-
0.37 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 148.90, 145.45, 
143.20, 126.11, 122.91 (5 x C), 112.51, 111.00 (2 x CH), 74.67 
(CH2), 45.36 (C), 38.95, 23.78 (2 x CH2), 10.00 (CH), 3.54 (CH2). 
HPLC: tR 1.67 min. MS (ESI+): m/z 320.5 [M+NH4]+. 
1-(5-(cyclopropylmethoxy)-4-hydroxy-2-
nitrophenyl)cyclopentane-1-carbonitrile (17); Prepared using 
general conditions (d) from benzyl aryl ether 15. (95%) pale yel-
low oil. 1H NMR (400 MHz, CDCl3) δ 7.36 (s, 1H), 7.02 (s, 1H), 
3.98 (d, J = 7.2 Hz, 2H), 1.86 (s, 6H), 1.36-1.24 (m, 1H), 0.74-
0.70 (m, 2H), 0.42-0.39 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
152.20, 148.01, 142.60, 127.54, 122.82 (5 x C), 113.00, 111.38 (2 
x CH), 74.40, 66.14 (2 x CH2), 45.34 (C), 41.16, 38.96, 31.92, 
23.82 (4 x CH2), 10.10 (C), 3.40 (CH2). HPLC: tR 1.88 min. MS 
(ESI+): m/z 379.3 [M+H]+. 
1-(4-(3-chloropropoxy)-5-(cyclopropylmethoxy)-2-
nitrophenyl)cyclopentane-1-carbonitrile (18); Prepared using 
general conditions (e) from phenol 16. (92%) yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 6.97 (s, 1H), 4.21 (t, J = 
5.9 Hz, 2H), 3.93 (d, J = 6.9 Hz, 2H), 3.77 (t, J = 6.2 Hz, 2H), 
2.74-2.62 (m, 2H), 2.33-2.27 (m, 2H), 2.10-1.96 (m, 4H), 1.95-
1.82 (m, 2H), 1.34-1.24 (m, 1H), 0.70-0.66 (m, 2H), 0.41-0.37 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ 152.20, 148.01, 142.60, 
127.54, 122.82 (5 x C), 113.00, 111.38 (2 x CH), 74.40, 66.14 (2 
x CH2), 45.34 (C), 41.16, 38.96, 31.92, 23.82 (4 x CH2), 10.10 
(C), 3.40 (CH2). HPLC: tR 1.88 min. MS (ESI+): m/z 379.3 
[M+H]+. 
2-(4-(3-chloropropoxy)-5-(cyclopropylmethoxy)-2-
nitrophenyl)-2-methylpropanenitrile (19); Prepared using gen-
eral conditions (e) from phenol 17. (99%) yellow solid. 1H NMR 
(400 MHz, CDCl3) δ 7.37 (s, 1H), 7.03 (s, 1H), 4.20 (t, J = 5.8 
Hz, 2H), 3.94 (d, J = 6.8 Hz, 2H), 3.77 (t, J = 6.2 Hz, 2H), 2.32-
2.26 (m, 2H), 1.86 (s, 6H), 1.34-1.23 (m, 1H), 0.69-0.65 (m, 2H), 
0.40-0.36 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 152.15, 
147.94, 142.32, 127.85, 122.97 (5 x C), 112.18, 111.31 (2 x CH), 
74.38, 66.15, 41.18 (3 x CH2), 36.20 (C), 31.92 (CH2), 28.45 
(CH3), 10.08 (CH), 3.38 (CH2). HPLC: tR 1.88 min. MS (ESI+): 
m/z 370.6 [M+NH4]+. 
1-(4-(4-chlorobutoxy)-5-(cyclopropylmethoxy)-2-
nitrophenyl)cyclopentane-1-carbonitrile (20); Prepared using 
general conditions (e) from phenol 16. (87%) yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 6.96 (s, 1H), 4.10 (t, J = 
5.7 Hz, 2H), 3.93 (d, J = 6.9 Hz, 2H), 3.67 (t, J = 6.2 Hz, 2H), 
2.72-2.64 (m, 2H), 2.09-1.96 (m, 8H), 1.96-1.79 (m, 2H), 1.36-
1.25 (m, 1H), 0.71-0.66 (m, 2H), 0.41-0.37 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 152.12, 148.16, 142.62, 127.28, 122.84 (5 x 
C), 112.93, 110.96 (2 x CH), 74.43, 68.95 (2 x CH2), 45.34 (C), 
44.59, 38.95, 29.41, 26.92, 26.31, 23.82 (6 x CH2), 10.11 (CH), 
3.39 (CH2). HPLC: tR 1.92 min. MS (ESI+): m/z 393.4 [M+H]+. 
2-(4-(4-chlorobutoxy)-5-(cyclopropylmethoxy)-2-
nitrophenyl)-2-methylpropanenitrile (21); Prepared using gen-
eral conditions (e) from phenol 17. (100%) yellow solid. 1H NMR 
(400 MHz, CDCl3) δ 7.33 (s, 1H), 7.03 (s, 1H), 4.09 (t, J = 5.8 
Hz, 2H), 3.94 (d, J = 6.9 Hz, 2H), 3.66 (t, J = 6.3 Hz, 1H), 2.03-
1.98 (m, 4H), 1.87 (s, 6H), 1.35-1.25 (m, 1H), 0.71-0.65 (m, 2H), 
0.41-0.36 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 152.04, 
148.09, 142.33, 127.57, 123.02 (5 x C), 112.14, 110.89 (2 x CH), 
74.41, 68.96, 44.60 (3 x CH2), 36.26 (C), 29.40 (CH2), 28.43 
(CH3), 26.30 (CH2), 10.09 (CH), 3.38 (CH2). HPLC: tR 1.93 min. 
MS (ESI+): m/z 384.7 [M+H]+. 
5'-(cyclopropylmethoxy)-6'-(3-(5-methoxyisoindolin-2-
yl)propoxy)spiro[cyclopentane-1,3'-indol]-2'-amine (22); Pre-
pared using general conditions (f) and (i) from alkyl chloride 18. 
(42%) white solid. 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 8.1 
Hz, 1H), 6.81 (s, 1H), 6.80 (s, 1H), 4.11 (t, J = 6.4 Hz, 2H), 3.92 
(s, 2H), 3.89 (s, 2H), 3.80 (d, J = 6.9 Hz, 2H), 3.78 (s, 3H), 2.92 
(t, J = 7.3 Hz, 2H), 2.12-1.90 (m, 10H), 1.31-1.21 (m, 1H), 0.60-
0.56 (m, 2H), 0.33-0.30 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
179.61, 158.96, 150.02, 148.75, 144.07, 141.62, 134.90, 132.20 (8 
x C), 122.86, 112.51, 112.04, 107.97, 103.30 (5 x CH), 76.63, 
67.54, 59.40, 58.59 (4 x CH2), 58.58 (C), 55.47 (CH3), 53.01, 
 
38.16, 28.98, 26.60 (4 x CH2), 10.87 (CH), 3.16 (CH2). HPLC: 
98%, tR 1.39 min. MS (ESI+): m/z 462.8 [M+H]+. 
5'-(cyclopropylmethoxy)-6'-(3-(isoindolin-2-
yl)propoxy)spiro[cyclopentane-1,3'-indol]-2'-amine (23); Pre-
pared using general conditions (f) and (i) from alkyl chloride 18. 
(45%) white solid. 1H NMR (400 MHz, CDCl3) δ 7.23-7.16 (m, 
4H), 6.82 (s, 2H), 4.13 (t, J = 6.3 Hz, 2H), 3.96 (s, 4H), 3.81 (d, J 
= 6.9 Hz, 2H), 2.94 (t, J = 7.4 Hz, 2H), 2.16-1.88 (m, 10H), 1.32-
1.22 (m, 1H), 0.62-0.56 (m, 2H), 0.35-0.30 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 179.36, 150.04, 149.09, 144.16, 140.16, 
135.14 (6 x C), 126.65, 122.27, 112.02, 103.56 (4 x CH), 76.64, 
67.55, 59.21 (3 x CH2), 58.64 (C), 52.99, 38.09, 29.00, 26.62 (4 x 
CH2), 10.87 (CH), 3.16 (CH2). HPLC: 100%, tR 1.40 min. MS 
(ESI+): m/z 432.7 [M+H]+. 
5'-(cyclopropylmethoxy)-6'-(4-(isoindolin-2-
yl)butoxy)spiro[cyclopentane-1,3'-indol]-2'-amine (24); Pre-
pared using general conditions (f) and (i) from alkyl chloride 20. 
(44%) white solid. 1H NMR (400 MHz, CDCl3) δ 7.21-7.16 (m, 
4H), 6.82 (s, 1H), 6.80 (s, 1H), 4.05 (t, J = 6.4 Hz, 2H), 3.93 (s, 
4H), 3.81 (d, J = 7.0 Hz, 2H), 2.79 (t, J = 7.3 Hz, 2H), 2.10-1.88 
(m, 10H), 1.82-1.74 (m, 2H), 1.33-1.22 (m, 1H), 0.61-0.54 (m, 
2H), 0.35-0.30 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 179.49, 
150.10, 149.06, 144.09, 140.21, 140.21, 134.97 (7 x C), 126.62, 
122.25, 112.08, 103.36 (4 x CH), 76.63, 69.07, 59.11 (3 x CH2), 
58.64 (C), 55.84, 38.11, 27.28, 26.61, 25.61 (5 x CH2), 10.88 
(CH), 3.16 (CH2). HPLC: 100%, tR 1.40 min. MS (ESI+): m/z 
446.7 [M+H]+. 
5-(cyclopropylmethoxy)-6-(3-(isoindolin-2-yl)propoxy)-3,3-
dimethyl-3H-indol-2-amine (25); Prepared using general condi-
tions (f) and (i) from alkyl chloride 19. (42%) white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.22-7.16 (m, 4 H), 6.84 (s, 1H), 6.79 
(s, 1H), 4.13 (t, J = 6.3 Hz, 2H), 3.96 (s, 4H), 3.82 (d, J = 6.9 Hz, 
2H), 2.95 (t, J = 7.4, 2H), 2.15-2.07 (m, 2H), 1.33-1.23 (m, 7H), 
0.63-0.55 (m, 2H), 0.36-0.29 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 179.11, 150.11, 147.80, 144.45, 140.14, 133.12 (6 x C), 
126.66, 122.27, 111.42, 103.69 (4 x CH), 76.31, 67.61, 59.20, 
52.96 (4 x CH2), 48.73 (C), 28.96 (CH2), 25.08 (CH3), 10.81 
(CH), 3.16 (CH2). HPLC: 99%, tR 1.34 min. MS (ESI+): m/z 
406.7 [M+H]+. 
5-(cyclopropylmethoxy)-6-(4-(isoindolin-2-yl)butoxy)-3,3-
dimethyl-3H-indol-2-amine (26); Prepared using general condi-
tions (f) and (i) from alkyl chloride 21. (39%) white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.21-7.16 (m, 4H), 6.83 (s, 1H), 6.79 
(s, 1H), 4.06 (t, J = 6.4 Hz, 2H), 3.93 (s, 4H), 3.82 (d, J = 6.9 Hz, 
2H), 2.79 (t, J = 7.4 Hz, 2H), 1.98-1.87 (m, 2H), 1.84-1.75 (m, 
2H), 1.32-1.21 (m, 7H), 0.61-0.54 (m, 2H), 0.37-0.28 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 179.22, 150.13, 148.57, 144.25, 
140.19, 133.28 (6 x C), 126.61, 122.24, 111.47, 103.68 (4 x CH), 
76.33, 69.10, 59.10, 55.84 (4 x CH2), 48.77 (C), 27.27, 25.59 (2 x 
CH2), 25.09 (CH3), 10.83 (CH), 3.16 (CH2). HPLC: 95%, tR 1.34 
min. MS (ESI+): m/z 420.8 [M+H]+. 
5-(prop-2-yn-1-yloxy)isoindoline (27); Propargyl bromide (80 
wt% in toluene, 0.30 ml, 2.81 mmol, 1.1 eq) was added to a stir-
ring mixture of tert-butyl 5-hydroxyisoindoline-2-carboxylate 
(0.600 g, 2.55 mmol, 1 eq) and potassium carbonate (0.705 g, 
5.10 mmol, 2 eq) in ACN (20 mL), and the mixture was stirred at 
40 °C overnight. The solvent was evaporated and the residue was 
purified by automated flash chromatography using a gradient 
elution of 0-5% MeOH in DCM (and using Seebach’s TLC stain 
to visualize the product) to give a colorless oil (0.630 g, 2.30 
mmol, 90%). The oil was dissolved in dry DCM (20 mL) and 
trifluoroacetic acid (TFA, 2 mL) was added. The solution was 
stirred at room temperature for approximately 2 h. The solvent 
was evaporated and the residue was purified by automated flash 
chromatography using a gradient elution of 0-10% of [7 N NH3 in 
MeOH] in DCM (and using ninhydrin TLC stain to visualize the 
product) to give compound 27 (0.413 g, 2.38 mmol, 93% (84% 
overall)) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 7.16 (d, 
J = 8.2 Hz, 1H), 6.90-6.82 (m, 2H), 4.69 (d, J = 2.4 Hz, 2H), 4.23 
(s, 2H), 4.20 (s, 2H), 2.51 (t, J = 2.4 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 157.02, 143.17, 134.49 (3 x C), 122.90, 113.85, 
109.01 (3 x CH), 78.66 (C), 75.45 (CH), 56.12, 53.04, 52.29 (3 x 
CH2). HPLC: tR 0.71 min. MS (ESI+): m/z 174.2 [M+H]+. 
5-(but-3-yn-1-yloxy)isoindoline (28); But-3-yn-1-ol (0.39 ml, 
5.10 mmol, 1.2 eq) was added to a solution of tert-butyl 5-
hydroxyisoindoline-2-carboxylate (1.000 g, 4.25 mmol, 1 eq) and 
triphenylphosphine (1.115 g, 4.25 mmol, 1 eq) in dry THF (20 
mL) under N2. The solution was cooled to 0 °C and diethyl azodi-
carboxylate (DEAD, 0.669 ml, 4.25 mmol, 1 eq) was added. The 
solution was heated at 60 °C for 5 h. The solvent was evaporated 
and the residue was purified by automated flash chromatography 
using a gradient elution of 50-100% DCM in cyclohexane (and 
using Seebach’s TLC stain to visualize the product) to a colorless 
oil (0.509 g, 1.77 mmol, 42%). The oil was dissolved in dry DCM 
(20 mL) and trifluoroacetic acid (TFA, 2 mL) was added. The 
solution was stirred at room temperature for approximately 2 h. 
The solvent was evaporated and the residue was purified by au-
tomated flash chromatography using a gradient elution of 0-10% 
of [7 N NH3 in MeOH] in DCM (and using ninhydrin TLC stain 
to visualize the product) to give compound 28 (0.302 g, 1.61 
mmol, 91% (38% overall)) as a brown solid. 1H NMR (400 MHz, 
CDCl3) δ 7.13 (d, J = 8.2 Hz, 1H), 6.83-6.72 (m, 2H), 4.20 (s, 
2H), 4.18 (s, 2H), 4.08 (t, J = 7.0 Hz, 2H), 2.67 (td, J = 7.0, 2.7 
Hz, 2H), 2.04 (t, J = 2.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
157.87, 143.29, 134.07 (3 x C), 122.90, 113.57, 108.70 (3 x CH), 
80.46 (C), 69.87 (CH), 66.33, 53.06, 52.31, 19.56 (4 x CH2). 
HPLC: tR 1.00 min. MS (ESI+): m/z 188.2 [M+H]+. 
2-(5-(cyclopropylmethoxy)-2-nitro-4-(3-(5-(prop-2-yn-1-
yloxy)isoindolin-2-yl)propoxy)phenyl)-2-methylpropanenitrile 
(29); Prepared using general conditions (f) from alkyl chloride 19 
and alkyne functionalized isoindoline 27. (96%) brown oil. 1H 
NMR (400 MHz, CDCl3) δ 7.37 (s, 1H), 7.12 (d, J = 8.0 Hz, 1H), 
7.04 (s, 1H), 6.85-6.80 (m, 2H), 4.67 (d, J = 2.4 Hz, 2H), 4.19 (t, 
J = 6.4 Hz, 2H), 4.00-3.90 (m, 6H), 2.95 (t, J = 6.9 Hz, 2H), 2.50 
(t, J = 2.4 Hz, 1H), 2.19-2.09 (m, 2H), 1.87 (s, 6H), 1.36-1.25 (m, 
1H), 0.74-0.62 (m, 2H), 0.46-0.34 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 157.05, 151.91, 148.33, 142.46, 141.03, 132.57, 127.30, 
123.09 (8 x C), 123.00, 113.85, 112.48, 110.96, 109.25 (5 x CH), 
78.62 (C), 75.46 (CH), 74.47, 67.66, 59.26, 58.51, 56.13, 52.46 (6 
x CH2), 36.34 (C), 28.39 (CH3), 28.21 (CH2), 10.14 (CH), 3.42 
(CH2). HPLC: tR 1.75 min. MS (ESI+): m/z 490.4 [M+H]+. 
2-(4-(3-(5-(but-3-yn-1-yloxy)isoindolin-2-yl)propoxy)-5-
(cyclopropylmethoxy)-2-nitrophenyl)-2-methylpropanenitrile 
(30); Prepared using general conditions (f) from alkyl chloride 19 
and alkyne functionalized isoindoline 28. (98%) brown oil. 1H 
NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 7.10 (d, J = 8.0 Hz, 1H), 
7.03 (s, 1H), 6.79-6.74 (m, 2H), 4.19 (t, J = 6.4 Hz, 2H), 4.07 (t, J 
= 7.1 Hz, 2H), 3.98-3.90 (m, 6H), 2.94 (t, J = 7.0 Hz, 2H), 2.66 
(td, J = 7.0, 2.7 Hz, 2H), 2.17-2.11 (m, 2H), 2.03 (t, J = 2.7 Hz, 
1H), 1.87 (s, 6H), 1.36-1.25 (m, 1H), 0.70-0.65 (m, 2H), 0.42-
0.38 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 157.92, 151.92, 
148.33, 142.45, 141.10, 132.11, 127.30, 123.08 (7 x C), 123.01, 
113.61, 112.46, 110.96, 108.97 (5 x CH), 80.44 (C), 74.47 (CH2), 
69.87 (CH), 67.67, 66.35, 59.26, 58.51, 52.47 (5 x CH2), 36.30 
(C), 28.40 (CH3), 28.21, 19.54 (CH2), 10.14 (CH), 3.42 (CH2). 
HPLC: tR 1.77 min. MS (ESI+): m/z 504.4 [M+H]+. 
2-(5-(cyclopropylmethoxy)-2-nitro-4-(4-(5-(prop-2-yn-1-
yloxy)isoindolin-2-yl)butoxy)phenyl)-2-methylpropanenitrile 
(31); Prepared using general conditions (f) from alkyl chloride 21 
and alkyne functionalized isoindoline 27. (52%) brown oil. 1H 
NMR (400 MHz, CDCl3) δ 7.34 (s, 1H), 7.11 (d, J = 8.0 Hz, 1H), 
 
7.03 (s, 1H), 6.86-6.78 (m, 2H), 4.67 (d, J = 2.4 Hz, 2H), 410 (t, J 
= 6.4 Hz, 2 H), 3.98-3.85 (m, 6H), 2.81 (t, J = 7.2 Hz, 2H), 2.50 
(t, J = 2.4 Hz, 1H), 2.0-1.94 (m, 2H), 1.87 (s, 6H), 1.82-1.74 (m, 
2H), 1.36-1.26 (m, 1H), 0.70-0.63 (m, 2H), 0.42-0.38 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 156.94, 151.94, 148.31, 142.40, 
141.40, 132.95, 127.23, 123.08 (8 x C), 122.95, 113.66, 112.30, 
110.66, 109.23 (5 x CH), 78.95 (C), 75.44 (CH), 74.44, 69.36, 
59.20, 58.44, 56.11, 55.59 (6 x CH2), 36.25 (C), 28.44 (CH3), 
26.70, 25.21 (2 x CH2), 10.15 (CH), 3.44 (CH2). HPLC: tR 1.75 
min. MS (ESI+): m/z 504.4 [M+H]+. 
2-azido-1-(4-(2-(pyrrolidin-1-yl)ethyl)piperidin-1-yl)ethan-
1-one (32); 2-Azidoacetic acid (0.23 ml, 3.03 mmol, 1.3 eq) was 
added to a stirring solution of p-toluenesulfonyl chloride (0.489 g, 
2.57 mmol, 1.1 eq) and diisopropylaminomethyl-polystyrene resin 
(3 mmol/g, 2.333 g, 3 eq) in dry DCM (20 mL), and the mixture 
was stirred a room temperature for 1 h. 4-(2-(Pyrrolidin-1-
yl)ethyl)piperidine (0.425 g, 2.33 mmol, 1 eq) was added and the 
mixture was stirred for a further 1 h. The mixture was filtered, and 
the filtrate was washed with Na2CO3 (1 M, 50 mL), dried 
(Na2SO4) and evaporated to give compound 32 (0.5217 g, 1.966 
mmol, 84%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 4.55 
(d, J = 13.3 Hz, 1H), 3.92 (s, 1H), 3.61 (d, J = 13.5 Hz, 1H), 3.02 
(td, J = 13.0, 2.8 Hz, 0H), 2.62 (td, J = 12.9, 2.9 Hz, 1H), 2.55-
2.40 (m, 6H), 1.84-1.71 (m, 6H), 1.65-1.45 (m, 3H),1.22-1.08 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ 165.27 (C), 54.26, 53.77, 
50.78, 45.39, 42.49, 35.36 (6 x CH2), 34.29 (CH), 32.75, 31.82, 
23.40 (3 x CH2). HPLC: tR 0.67 min. MS (ESI+): m/z 266.3 
[M+H]+. 
3-azido-1-(4-(2-(pyrrolidin-1-yl)ethyl)piperidin-1-
yl)propan-1-one (33); 3-Azidopropanoic acid (0.24 mL, 2.60 
mmol, 1.3 eq) was added to a stirring solution of p-
toluenesulfonyl chloride (0.418 g, 2.20 mmol, 1.1 eq) and resin-
bound diisopropylaminomethyl-polystyrene (3 mmol/g, 2.000 g 3 
eq) in dry DCM (20 mL), and the mixture was stirred a room 
temperature for 1 h. 4-(2-(Pyrrolidin-1-yl)ethyl)piperidine (0.365 
g, 2.00 mmol, 1 eq) was added and the mixture was stirred for a 
further 1 h. The mixture was filtered, and the filtrate was washed 
with Na2CO3 (1 M, 50 mL), dried (Na2SO4) and evaporated to 
give crude compound 33 (89% but with a purity of approx. 90%) 
as a yellow solid. Compound 33 was unstable and following the 
workup, approximately 10% of an alkene by-product had formed 
(presumably caused by elimination of the azide during evapora-
tion) and therefore, was not characterized, but was used immedi-
ately as a crude mixture in the proceeding click reaction. 
General conditions (j); Copper powder (<425 µm, 25 eq), az-
ide 32 or 33 (2 eq) and alkyne 29, 30 or 31 (0.20 mmol, 1 eq) 
were stirred vigorously in DMF (5 mL) at 60 °C, under N2, until 
all the alkyne starting material had been consumed (approx. 2 h). 
The cooled reaction mixture was evaporated and the residue was 
purified by automated flash chromatography using a gradient 




yl)ethyl)piperidin-1-yl)ethan-1-one (34); Prepared using general 
conditions (j) and (i) from alkyne 29 and azide 32. (17%) white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.08 (d, J = 8.1 
Hz, 1H), 6.85-6.76 (m, 4H), 5.26-5.16 (m, 4H), 4.51 (d, J = 13.4 
Hz, 1H), 4.11 (t, J = 6.2 Hz, 2H), 3.91-3.78 (m, 7H), 3.11 (t, J = 
6.5 Hz, 1H), 2.91 (t, J = 7.3 Hz, 2H), 2.64 (t, J = 13.0 Hz, 1H), 
2.55-2.45 (m, 6H), 2.11-2.05 (m, 2H), 1.84-1.72 (m, 6H), 1.68-
1.54 (m, 1H), 1.54-1.45 (m, 2H), 1.36-1.21 (m, 7H), 1.21-1.08 (m, 
2H), 0.64-0.56 (m, 2H), 0.34-0.29 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 179.37, 162.92, 157.57, 150.37, 147.91, 144.89, 144.55, 
141.67, 133.39, 132.81 (10 x C), 124.43, 122.97, 113.57, 111.46, 
109.08, 102.28 (6 x CH), 76.23, 67.58, 62.32, 59.34, 58.55, 54.15, 
53.64, 52.84, 51.05 (9 x CH2), 48.26 (C), 45.67, 42.75, 35.03 (3 x 
CH2), 34.17 (CH), 32.62, 31.68, 28.85 (3 x CH2), 25.09 (CH3), 
23.39 (CH2), 10.75 (CH), 3.17 (CH2). HPLC: 98%, tR 1.20 min. 




1-yl)ethan-1-one (35); Prepared using general conditions (j) and 
(i) from alkyne 30 and azide 32. (47%) white solid. 1H NMR (400 
MHz, CDCl3) δ 7.62 (s, 1H), 7.06 (d, J = 6.5 Hz, 1H), 6.82 (s, 
1H), 6.78-6.70 (m, 3H), 5.24-5.14 (m, 2H), 4.51 (d, J = 13.4 Hz, 
1H), 4.22 (t, J = 6.5 Hz, 2H), 4.11 (t, J = 6.3 Hz, 2H), 3.93-3.76 
(m, 7H), 3.21 (t, J = 6.5 Hz, 2H), 3.09 (td, J = 13.2, 2.5 Hz, 1H), 
2.91 (t, J = 7.3 Hz, 2H), 2.63 (td, J = 12.9, 2.6 Hz, 1H), 2.53-2.41 
(m, 6H), 2.13-2.03 (m, 2H), 1.84-1.70 (m, 6H), 1.66-1.53 (m, 
1H), 1.52-1.42 (m, 2H), 1.35-1.21 (m, 7H), 1.19-1.04 (m, 2H), 
0.62-0.54 (m, 2H), 0.36-0.27 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 179.3, 163.2, 158.0, 150.0, 148.3, 144.9, 144.2, 141.7, 
133.3, 132.5, (10 x C), 123.5, 122.9, 113.2, 111.4, 108.8, 103.6 (6 
x CH), 76.3, 67.6, 67.0, 59.4, 58.6, 54.3, 53.7, 53.0, 51.1 (9 x 
CH2), 48.7 (C), 45.7, 42.7, 35.3 (3 x CH2), 34.2 (CH), 32.6, 31.7, 
29.0, 26.4 (4 x CH2), 25.1 (CH3), 23.4 (CH2), 10.8 (CH), 3.2 





yl)ethyl)piperidin-1-yl)propan-1-one (36); Prepared using gen-
eral conditions (j) and (i) from alkyne 29 and azide 33. (31%) 
while solid. 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.08 (d, J 
= 8.2 Hz, 1H), 6.86-6.75 (m, 4H), 5.15 (s, 2H), 4.70 (t, J = 6.3 Hz, 
2H), 4.51 (d, J = 13.3 Hz, 2H), 4.11 (t, J = 6.3 Hz, 2H), 3.91 (s, 
2H), 3.88 (s, 2H), 3.81 (d, J = 6.9 Hz, 2H), 3.71 (d, J = 13.4 Hz, 
2H), 2.97-2.87 (m, 5H), 2.58-2.41 (m, 7H), 2.13-2.03 (m, 2H), 
1.82-1.66 (m, 6H), 1.60-1.42 (m, 3H), 1.35-1.22 (m, 7H), 1.14-
0.98 (m, 2H), 0.61-0.54 (m, 2H), 0.34-0.28 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 179.26, 167.35, 157.60, 150.05, 148.39, 
144.28, 143.84, 141.70, 133.31, 132.82 (10 x C), 124.25, 122.94, 
113.49, 111.43, 108.99, 103.75 (6 x CH), 76.32, 67.57, 62.24, 
59.37, 58.57, 54.24, 53.79, 52.97 (8 x CH2), 48.73 (C), 46.16, 
45.58, 42.16, 35.35 (4 x CH2), 34.32 (CH), 33.56, 32.65, 31.86, 
28.96 (4 x CH2), 25.07 (CH3), 23.39 (CH2), 10.82 (CH), 3.16 





1-yl)propan-1-one (37); Prepared using general conditions (j) 
and (i) from alkyne 30 and azide 33. (14%) while solid. 1H NMR 
(400 MHz, CDCl3) δ 7.58 (s, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.83 
(s, 1H), 7.06-6.83 (m, 3H), 4.67 (t, J = 6.5 Hz, 2H), 4.52 (d, J = 
12.9 Hz, 1H), 4.20 (t, J = 6.6 Hz, 2H), 4.12 (t, J = 6.3 Hz, 2H), 
3.91 (s, 2H), 3.88 (s, 2H), 3.81 (d, J = 7.0 Hz, 2H), 3.72 (d, J = 
14.0 Hz, 1H), 3.17 (t, J = 6.6 Hz, 2H), 2.97-2.88 (m, 5H), 2.56-
2.44 (m, 7H), 2.12-2.05 (m, 2H), 1.84-1.66 (m, 6H), 1.60-1.43 (m, 
3H), 1.35-1.20 (m, 7H), 1.11-0.98 (m, 2H), 0.62-0.54 (m, 2H), 
0.36-0.27 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 179.10, 
167.51, 158.00, 150.09, 147.97, 144.41, 144.28, 141.67, 133.19, 
132.48 (10 x C), 123.29, 122.92, 113.28, 111.41, 108.78, 103.73 
(6 x CH), 76.31, 67.59, 67.10, 59.37, 58.59, 54.22, 53.77, 52.98 (8 
x CH2), 48.72 (C), 46.02, 45.58, 42.13, 35.18 (4 x CH2), 34.18 
(CH), 33.58, 32.64, 31.86, 28.94, 26.17 (5 x CH2), 25.07 (CH3), 
23.39 (CH2), 10.81 (CH), 3.16 (CH2). HPLC: 98%, tR 1.21 min. 





1-yl)ethan-1-one (38); Prepared using general conditions (j) and 
(i) from alkyne 31 and azide 32. (54%) while solid. 1H NMR (400 
MHz, CDCl3) δ 7.78 (s, 1H), 7.07 (d, J = 8.0 Hz, 1H), 6.83-6.76 
(m, 4H), 5.26-5.16 (m, 4H), 4.51 (d, J = 13.4 Hz, 2H), 4.05 (t, J = 
6.3 Hz, 2H), 3.91-3.77 (m, 7 H) 3.11 (td, J = 13.0, 2.8 Hz, 1H), 
2.76 (t, J =  7.3 Hz, 2H), 2.65 (td, J = 13.0, 3.0 Hz, 1H), 2.56-2.43 
(m, 6H), 1.96-1.86 (m, 2H), 1.86-1.70 (m, 8 H), 1.67-1.54 (m, 
1H), 1.54-1.45 (m, 2H), 1.36-1.22 (m, 7 H), 1.22-1.07 (m, 2H), 
0.62-0.54 (m, 2H), 0.36-0.27 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 179.20, 162.93, 157.53, 150.11, 147.92, 144.50, 144.33, 
141.72, 133.03, 132.87 (10 x C), 124.46, 122.93, 113.46, 111.42, 
109.09, 103.51 (6 x CH), 76.28, 69.09, 62.29, 59.24, 58.48, 55.83, 
54.24, 53.70, 51.05 (9 x CH2), 48.72 (C), 45.66, 42.76, 35.19 (3 x 
CH2), 34.17 (CH), 32.62, 31.69, 27.25, 25.52 (4 x CH2), 25.07 
(CH3), 23.40 (CH2), 10.82 (CH), 3.17 (CH2). HPLC: 99%, tR 1.41 
min. MS (ESI+): m/z 740.1 [M+H]+, 370.8 [M+2H]2+. 
5-(Benzyloxy)isoindoline (39); Prepared by O-benzylation of 
tert-butyl 5-hydroxyisoindoline-2-carboxylate (0.590 g, 2.51 
mmol, 1 eq) using condition (e). The resultant oil was dissolved in 
dry DCM (20 mL) and trifluoroacetic acid (TFA, 2 mL) was add-
ed. The solution was stirred at room temperature for approximate-
ly 2 h. The solvent was evaporated and the residue was purified 
by automated flash chromatography using a gradient elution of 0-
10% of [7 N NH3 in MeOH] in DCM (and using ninhydrin TLC 
stain to visualize the product) to give compound 39 (0.500 g, 2.22 
mmol, 89%) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 
7.47-7.29 (m, 5H), 7.14 (d, J = 8.1 Hz, 1H), 6.89-6.82 (m, 2H), 
5.06 (s, 2H), 4.20 (s, 2H), 4.18 (s, 2H). 13C NMR (101 MHz, 
CDCl3) δ 158.34, 143.15, 137.15, 133.77 (4 x C), 128.61, 128.58, 
127.95, 127.45, 122.92, 113.82, 108.87 (6 x CH), 70.31, 53.05, 




Prepared using general conditions (f) and (i) from alkyl chloride 
19 and isoindoline 39. (63%) while solid. 1H NMR (400 MHz, 
CDCl3) δ 7.44-7.28 (m, 5H), 7.10 (d, J = 8.0 Hz, 1H), 6.86-6.79 
(m, 4H), 5.04 (s, 2H), 4.12 (t, J = 6.2 Hz, 2H), 3.97 (s, 2H), 3.95 
(s, 2H), 3.81 (d, J = 6.9 Hz, 2H), 2.97 (t, J = 7.4 Hz, 2H), 2.17-
2.08 (m, 2H), 1.45 (s, 6H), 1.32-1.22 (m, 1H), 0.63-0.57 (m, 2H), 
0.36-0.31 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 178.80, 
158.28, 149.68, 148.70, 143.87, 141.78, 136.70, 134.09, 131.96 (9 
x C), 128.58, 127.92, 127.44, 123.00, 113.76, 110.99, 109.07, 
104.32 (8 x CH), 75.96, 70.27, 67.63, 59.34, 58.59, 52.90, 48.37 
(C), 28.58 (CH2), 25.05 (CH3), 10.66 (CH), 3.21 (CH2). HPLC: tR 
1.50 min. MS (ESI+): m/z 512.4 [M+H]+. 
Conditions (k); Synthesis of 6-(3-(5-(4-
aminobutoxy)isoindolin-2-yl)propoxy)-5-
(cyclopropylmethoxy)-3,3-dimethyl-3H-indol-2-amine (41); 
Palladium (10% on carbon (50% wet), 0.2 weight eq) was added 
to a solution of benzyl aryl ether 40 (0.128 g, 0.25 mmol, 1 eq) in 
MeOH (50 mL). The system was flushed with N2, followed by H2 
and the mixture was stirred at room temperature under H2 for 18 
h. The catalyst was removed by filtration through a bed of celite® 
and the solvent was evaporated to give the debenzylated product, 
which was used without further purification. Potassium carbonate 
(69 mg, 0.50 mmol, 2 eq) and 4-(boc-amino)butyl bromide (71 
mg, 0.28 mmol, 1.1 eq) was added to the debenzylated product 
and the mixture was stirred in DMF (5 mL), at room temperature, 
for 48 hours. The reaction mixture was evaporated and the residue 
was directly loaded onto a Biotage® SNAP KP-NH column. The 
product was eluted with an eluent of 0-10% MeOH in DCM. The 
resultant white solid was dissolved in dry DCM (20 mL) and tri-
fluoroacetic acid (TFA, 2 mL) was added. The solution was 
stirred at room temperature for approximately 2 h. The solvent 
was evaporated and the residue was purified by automated flash 
chromatography using a gradient elution of 0-10% of [7 N NH3 in 
MeOH] in DCM (and using ninhydrin TLC stain to visualize the 
product) to give compound 41 (12 mg, 0.02 mmol, 12%) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.2 Hz, 
1H), 6.83 (s, 1H), 6.80-6.69 (m, 3H), 4.12 (t, J = 6.3 Hz, 2H), 
3.98-3.84 (m, 6H), 3.81 (d, J = 6.9 Hz, 2H), 2.92 (t, J = 7.3 Hz, 
3H), 2.77 (t, J = 7.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
179.20, 158.34, 150.09, 147.83, 144.34, 141.59, 133.05, 132.13 (8 
x C), 122.88, 113.22, 111.41, 108.65, 103.56 (5 x CH), 76.33, 
68.00, 67.55, 59.37, 58.61, 52.96 (6 x CH2), 48.70 (C), 41.88, 
30.20, 28.92, 26.70 (4 x CH2), 25.08 (CH3), 10.81 (CH), 3.18 
(CH2). HPLC: tR 1.15 min. MS (ESI+): m/z 493.6 [M+H]+. 
Construct design, cloning, expression and purification of 
human SPINDLIN proteins 
A plasmid encoding full length human SPIN1 was obtained 
from Source Bioscience (IOH9972-pDEST26) and used as a tem-
plate to clone SPIN1M26–S262 and SPIN1P49-S262 into the pNIC-
CTHF vector with a TEV (tobacco etch virus) cleavable C-
terminal His6 tag. SPIN1G21-S262 was cloned into the pNIC-Bio2 
vector with a TEV cleavable N-terminal His10 tag, and a C-
terminal biotinylation sequence. SPIN2BP45-S258, SPIN3M27-S258 
and SPIN4T36-P249 were cloned into the pNIC vector with a TEV 
cleavable N-terminal His6 tag using templates obtained from the 
Mammalian Gene Collection and Source Bioscience (SPIN2B: 
cDNA clone IMAGE id:6729986, SPIN3 IMAGENE: 
IRCBp5005F0211Q and SPIN4 IMAGE id 40032302). For crys-
tallization studies SPIN2BP45-S258 and SPIN3P45-S258 were also 
cloned into the pNIC-CTHF vector. The recombinant proteins 
were expressed in a phage-resistant derivative of Escherichia coli 
strain BL21(DE3) carrying the pRARE2 plasmid for rare codon 
expression. Cells were grown at 37 C in Terrific Broth supple-
mented with 50 μg/ml kanamycin and 34 μg/ml chloramphenicol, 
until the culture reached an OD600 of 2.0. The temperature was 
decreased to 18 C and protein expression induced with 0.1 mM 
IPTG (isopropyl β-D-thiogalactopyranoside) overnight. Cells 
were collected by centrifugation and frozen at −80 C. Biotinylat-
ed SPIN1G21-S262 was expressed similarly in a BL21(DE3)-R3-
pRARE2-BirA strain as described in reference 4.64 For purifica-
tion, cells were resuspended in 50 mM Hepes pH 7.5, 500 mM 
NaCl, 10 mM imidazole, 5 % glycerol, 0.5 mM TCEP and a pro-
tease inhibitor cocktail (Sigma), and lysed by sonication. The cell 
lysate was clarified by centrifugation and the proteins purified by 
nickel-affinity chromatography (GE Healthcare) using a stepwise 
gradient of imidazole. The histidine tag was removed by incubat-
ing SPIN1P49-S262, SPIN1G21-S262, SPIN2BP45-S258, SPIN3P45-S258 
and SPIN4T36-P249 with TEV protease at 4 C overnight and this 
was followed by size exclusion chromatography (Superdex 75 or 
Superdex 200, GE Healthcare) in 10 mM Hepes pH 7.5, 500 mM 
NaCl, 5 % glycerol and 0.5 mM TCEP. The TEV protease and the 
uncleaved proteins were removed by nickel-affinity chromatog-
raphy and concentrated using an Amicon centrifugal filtration 
unit. Mass of purified proteins was verified by electrospray ioni-
zation time of flight mass spectrometry (ESI-TOF-TOF: Agilent 
LC/MSD). 
Crystallization and X-ray data collection 
Proteins used for crystallization studies had the histidine tag 
removed, and all proteins were crystallized at 4 C using the sit-
ting drop vapor diffusion method. SPIN1Pro49-Ser262 was incubated 
with 4.5 mM A-366 at 31 mg/ml and crystals were obtained in a 
drop containing 100 nl of protein compound mixture, 30 nl pre-
cipitant consisting of 0.1 M Bis-Tris pH 6.5, 0.2 M CaCl2, 45% 
MPD and 20 nl seeds obtained from crystals grown in 0.1 M Bis-
Tris pH 5.5, 0.1 M MgCl2 and 16% PEG3350. The crystal was 
cryo protected in precipitant solution supplemented with 25% 
 
ethylene glycol before it was flash cooled in liquid nitrogen. 
SPIN1Pro49-Ser262 was incubated with 1.5 mM of either compound 
23 or compound 35 using 39 mg/ml protein. Crystals appeared in 
drops consisting of 75 nl protein compound mixture and 75 nl 
precipitant consisting of 55-60% MPD and 0.1 M SPG (Succinate, 
Phosphate and Glycine) buffer pH 5.5-6.0. SPIN2BP45-S258 was 
crystallized using 23 mg/ml protein preincubated with 3-fold mo-
lar excess of a ARTK(me3)QTAR(me2a)KS peptide. Crystals 
appeared in drops consisting of 100 nl SPIN2B/peptide and 50 nl 
precipitant composed of 0.1 M Bis-Tris buffer pH 5.5 and 25% 
PEG3350. SPIN3P45-S258 was crystallized in a drop consisting of 
75 nl 24 mg/mL protein, 55 nL precipitant compost of of 0.1M 
Tris buffer pH 8.4 and 38% PEG3350, and 20nl seeds prepared 
from crystals grown in the same condition. SPIN4T36-P249 was 
crystallized using 29 mg/mL protein preincubated with 1.7 mM 
ARTK(Me3)QTARKS peptide. Crystals were obtained in drops 
consisting of 50 nl protein /peptide, 80 nl precipitant compost of 
30% PEG3350 and 0.1 M HEPES pH 7.0 and 20 nl seeds pre-
pared from crystals grown in the same condition. Crystals of 
SPIN2B, SPIN3 and SPIN4 were cryo protected in precipitant 
solution supplemented with 25% ethylene glycol before they were 
flash cooled in liquid nitrogen. All data were collected on beam-
lines I02, I03 and I24 at the Diamond Light source UK. 
Structure determination 
All datasets were processed, scaled and merged at the Diamond 
light source using Xia2, autoPROC,65 XDS,66 POINTLESS,67 
AIMLESS,68 and CCP4.69 Electron density maps were obtained 
by molecular replacement using PHASER with previously deter-
mined structures of SPIN1 as a search model (pdb id 4H75 and 
4MZG). The complex structure of SPIN1 with A-366 was solved 
to 1.52 Å resolution (pdb 6I8Y), with compound 23 to 1.58 Å 
(pdb 6I8L) and with compound 35 to 1.76 Å resolution (pdb 
6I8B). SPIN2B was solved to 1.7 Å (pdb 5LUG), SPIN3 to 2.0 Å 
(pdb 5A1H) and SPIN4 to 1.86 Å resolution. All structures were 
refined in an iterative process combining REFMAC and 
PHENIX70 with electron density map inspections and model im-
provement in COOT71 and terminated when there were no signifi-
cant changes in the Rwork and Rfree values, and inspection of the 
electron density map suggested that no further corrections or addi-
tions were justified. Structural analysis and figures were per-
formed with PyMOL (http://www.pymol.org). 
AlphaScreen Assay 
Compound binding was determined by the displacement of a 
trimethylated biotinylated histone H3 peptide from a Hexa His 
tagged SPIN1 Tudor domain protein using an AlphaScreen® His-
tidine (Nickel Chelate) Detection Kit. Compound was dispensed 
from DMSO stocks into assay plates (ProxiPlate-384 Plus, Perkin 
Elmer) using an Echo 525 Liquid Handler (Labcyte). Assays were 
performed at 25 °C in a volume of 20 μL in a buffer that was 25 
mM HEPES pH7.5, 100mM NaCl, 0.1% BSA, 0.05% CHAPS 
with 12.5 nM peptide (ARTK(me3)QTARKSTGGKAPRK-
biotin), 12.5 nM SPIN1, 0.2 % DMSO. Peptide and protein 
(SPIN1M26–S262 C-terminal His6 tag) were pre-mixed, added to the 
compound plate and incubated for 30 minutes after which Al-
phaScreen® beads were added to a final concentration of 2.5 
μg/mL. Assay plates were incubated for 60 minutes then lumines-
cence was measured using a Pherastar FS/FSX (BMG). 
Bio-Layer Interferometry (BLI) Assay 
The direct interaction between small molecules and SPIN1 was 
measured using a BLI Octet RED384 (FortéBio Inc., Menlo Park, 
CA). Superstreptavidin biosensors (FortéBio Inc.) were coated in 
a solution containing 50 μg/mL of biotinylated protein (SPIN1G21-
S262 C-terminal biotinylation) for 5 min at 25 °C. Compound was 
dispensed from DMSO stocks into plates using an Echo 525 Liq-
uid Handler (Labcyte). Assays were performed at 25°C in a vol-
ume of 60 μL in a buffer that was 25 mM HEPES pH 7.5, 150 
mM NaCl and 0.05 % TWEEN 20. A duplicate set of sensors 
without protein was used as a background binding control. Asso-
ciation of samples (5000, 2500, 1250, 625, 312.5, 156.25 and 
78.125 nM) to coated and uncoated reference sensors was meas-
ured over 120 seconds and dissociation over 240 seconds. Data 
analysis on the FortéBio Octet RED96 instrument was performed 
using a double reference subtraction (sample and sensor refer-
ences) in the FortéBio data analysis software, which accounts for 
nonspecific binding, background, and signal drift and minimizes 
well-based and sensor variability, while Kd values were fitted 
using a 1:1 model. 
Thermal Shift Assay (TSA)/Differential Scanning Fluorime-
try 
TSA/DSF experiments for UHRF1, 53BP1, TDRD3, SND1, 
SETDB1 and SGF29 were carried out as reported by Neisen et 
al.29 All other TSA/DSF experiments were performed on a Light-
cycler480 (Roche Molecular Systems). Compounds were dis-
pensed into 384-well PCR plates (20 µl assay volume) to a final 
concentration of 20 µM. Purified proteins were diluted to 2 uM in 
buffer (20 mM HEPES, 500 mM, pH 7.5). SYPRO orange dye 
was added to a 1:1000 dilution from purchased stock (LifeTech-
nologies). Proteins were melted over a gradient from 20 to 95 °C 
with three acquisitions per cycle (0.19 °C/s). The shift in unfold-
ing (DTm) was calculated as the difference between the mean 
melting temperature (Tm) for DMSO reference wells (n = 16 per 
protein) and Tm for the compound wells (duplicates for each com-
pound). Tm was estimated by fitting a sigmoidal Boltzmann equa-
tion to the fluorescence intensity I(T) over the unfolding process: 
I(T) = Ionset + (Iend– Ibaseline)/1+e^((Tm-T)/S)) 
where Ionset is the intensity before the onset of unfolding, Iend is 
the intensity at the endpoint of unfolding and S is the slope of the 
curve. 
Isothermal Titration Calorimetry 
Purified protein was diluted (see SI Table S5) in ITC buffer 
(100 mM NaCl, 20 mM Tris, pH 8.0) and then dialyzed against a 
1000 times excess of ITC buffer at 4 C overnight using Snake-
Skin® Dialysis Tubing (Thermo Scientific) with a 3.5 kDa molec-
ular weight cut off. The dialyzed sample was then centrifuged at 
14.000 rpm in a standard chilled benchtop centrifuge at 4 C to 
remove aggregate. Protein concentration (see SI Table S5) was 
then verified via absorption at 280 nm using a NanoDrop ND1000 
Spectrophotometer. Compounds were diluted in ITC buffer (SI, 
Table S5). ITC was performed on a NanoITC Standard Volume 
instrument (TA Instruments) using direct titration (protein in cell, 
compound in syringe) at 20 C with an initial injection of 3.7 µL 
followed by 30 injections of 7.96 µL at a stir rate of 350 rpm. 
Data were analyzed using an independent fit model with the 
NanoAnalyse software (TA Instruments, version 3.4.0). 
Development of SPIN1 Nanobret assay 
U20S cell (2.8 x 105) were plated in each well of a 6-well plate. 
After 6h cells were co-transfected with C-terminal HaloTag-
Histone 3.3 (NM_002107) and an N-terminal NanoLuciferase 
fusion of full length SPIN1 at a 1:500 (NanoLuc® to HaloTag®) 
ratio respectively with FuGENE HD transfection regent. Sixteen 
hours post-transfection, cells were collected, washed with PBS, 
and exchanged into media containing phenol red-free DMEM and 
4% FBS in the absence (control sample) or the presence (experi-
mental sample) of 100 nM NanoBRET 618 fluorescent ligand 
(Promega). Cells were then re-plated in a 384-well assay white 
plate (Greiner #3570) at 2.7x103 cells per well. Compounds were 
then added directly to media at final concentrations of 0-30 μM or 
an equivalent amount of DMSO as a vehicle control, and the 
plates were incubated for 24 h at 37 C in the presence of 5% 
 
CO2. NanoBRET Nano-Glo substrate (Promega) was added to 
both control and experimental samples at a final concentration of 
10 µM. Readings were performed within 10 minutes using a Clar-
ioSTAR (BMG labtech). A corrected BRET ratio was calculated 
and is defined as the ratio of the emission at 610 nm/460 nm for 
experimental samples minus the emission at 610 nm/460 nm for 
control samples (without NanoBRET fluorescent ligand). BRET 
ratios are expressed as milliBRET units (mBU), where 1 mBU 
corresponds to the corrected BRET ratio multiplied by 1000. The 
assay was further validated by domain specific site directed muta-
genesis (Y170A) ablating peptide and ligand binding. 
Cell line screening-proliferation assays, cell cycle and apop-
tosis 
SCC040 cells were seeded into 96-well (proliferation) or 6 well 
plates (cell cycle and apoptosis) at a density of 500 and 15,000 
cells/well respectively in DMEM medium (supplemented with 
10% FCS, 2 mM L-Glutamine, 100 units/mL penicillin, 100 
ug/mL streptomycin, 1x NEAA) in the presence of 1 µM, 2 µM 
and 4 µM compound 35, 38 or DMSO control. To assess prolifer-
ation cells were measured for confluence, using brightfield imag-
ing on the Celigo (Nexcelome) and direct cell counting of cell 
nuclei within each well 1h by incubation of Hoechst 33342 at 10 
µg/mL at day 4 and day 6 after seeding. To assess cell cycle pa-
rameters, cells were trypsinized, pelleted and re-suspended in 0.5 
mL SSC040 media with 10 µg/mL Hoechst 33342 for 45 min at 
37 C, 5% CO2. Cells were then analyzed on a BD LSRFortessa™ 
and cell cycle measured using FlowJoV10. To assess apoptosis 
cells the Dead Cell Apoptosis Kit with Annexin V Alexa Fluor® 
488 and PI (Invitrogen) kit was used. In brief, cells were tryp-
sinized, washed in PBS, pelleted and re-suspended in 0.1 mL 1x 
Annexin Binding buffer. 1 µL of 100 µL/mL Propidium Iodide 
(PI) and 5 µl Alexa Fluor® 488 annexin V was added per sample 
and incubated at room temperature for 15 min in the dark. 0.4 mL 
Annexin Binding buffer was then added to each sample and cells 
were then analyzed on a BD LSRFortessa™ and apoptosis meas-
ured using FlowJoV10. 
Chemoproteomic - Preparation of affinity resin 
Amine functionalized compound 41 was coupled to NHS-
activated Sepharose 4 fast flow beads (GE Healthcare).72 100 µL 
of bead slurry (50% in isopropanol) were used for each pull-down 
experiment. Beads were washed with DMSO (500 µL), collected 
by centrifugation (3 min, 60 x g), and the supernatant removed. 
After three wash cycles, the beads were resuspended in DMSO 
(50 µL), to which the amine (0.025 µmol) and triethylamine (0.75 
µL) were added. The beads were incubated at room temperature 
for 16 hours, and depletion of free amine from the supernatant 
determined by LC-MS analysis. Ethanolamine (2.5 µL) was then 
added to block any unreacted NHS sites, and the beads incubated 
for a further 16 hours. Derivatized beads were then washed with 
DMSO (3 × 500 µL), Buffer A (50 mM Tris pH 7.5, 0.8% v/v 
NP-40, 5% v/v glycerol, 1.5 mM MgCl2, 100 mM NaCl, 25 mM 
NaF, 1 mM Na3VO4, 1 mM PMSF, 1 mM DTT, 10 µg/mL TLCK, 
1 µg/mL Leupeptin, 1 µg/mL Aprotinin, 1 µg/mL soy bean tryp-
sin) (3 × 1 mL). Resin was incubated with cell lysates (2 mg of 
protein per pulldown, at 6 mg/mL) that had been pre-treated with 
either compound 35, 38 (20 µM) or DMSO control for 30 minutes 
at 4 C. Beads and treated lysates were incubated for 2 hours at 4 
C, before being washed with Buffer A (5 mL) proteins were 
eluted by addition of 80 µL of 2x sample Buffer (65.8 mM Tris-
HCl pH 6.8, 26.3% (w/v) glycerol, 2.1% SDS, 0.01% bromophe-
nol blue, 50 mM DTT). Before MS analysis, SPIN1 pull-down 
was verified by Western Blotting using primary antibody 
ab118784 (Abcam UK, rabbit) at 1:1000. 
MS sample preparation 
Samples were reduced with DTT (10 mM final concentration) 
for 30 minutes at room temperature, alkylated with iodoacetamide 
(55 mM final concentration) for 30 minutes at room temperature, 
diluted with TEAB, and incubated with trypsin (6 µL, 0.2 mg/mL) 
overnight at 37 C. The digests were then desalted using SEPAC 
lite columns (Waters), eluted with 69% v/v MeCN, 0.1% v/v FA 
in H2O (1 mL) and dried in vacuo. Dried peptides were stored at -
20 C before resuspension in 2% V/V MeCN, 0.1% v/v FA in 
H2O (20 µL) for LC-MS/MS analysis. Mass spectrometry data 
was acquired at the Discovery Proteomics Facility (University of 
Oxford). Digested samples were analyzed by nano-UPLC–
MS/MS using a Dionex Ultimate 3000 nano UPLC with EASY 
spray column (75 µm × 500 mm, 2 µm particle size, Thermo Sci-
entific) with a 60 min gradient of 0.1% (v/v) formic acid in 5% 
(v/v) DMSO to 0.1% (v/v) formic acid with 35% (v/v) acetonitrile 
in 5% (v/v) DMSO at a flow rate of approximately 250 nL/min 
(600 bar per 40 C column temperature). Mass spectrometry data 
was acquired with an Orbitrap Q Exactive High Field (HF) in-
strument (ThermoFisher). Survey scans were acquired at a resolu-
tion of 60,000 at 400 m/z and the 20 most abundant precursors 
were selected for CID fragmentation.  
Data analysis 
Raw data was processed using MaxQuant version 1.5.0.253 and 
the reference complete human proteome FASTA file (UniProt). 
Label Free Quantification (LFQ) and Match Between Runs were 
selected; replicates were collated into parameter groups to ensure 
matching between replicates only. Cysteine carbamidomethyla-
tion was selected as a fixed modification, and methionine oxida-
tion as a variable modification. Default settings for identification 
and quantification were used. Specifically, a minimum peptide 
length of 7, a maximum of 2 missed cleavage sites and a maxi-
mum of 3 labelled amino acids per peptide were employed. Pep-
tides and proteins were identified utilizing a 0.01 false discovery 
rate, with “Unique and razor peptides” mode selected for both 
identification and quantification of proteins (razor peptides are 
uniquely assigned to protein groups and not to individual pro-
teins). At least 2 razor + unique peptides were required for valid 
quantification. Processed data was further analyzed using Perseus 
version 1.5.0.9 and Microsoft Excel 2010. Peptides categorized by 
MaxQuant as ‘potential contaminants’, ‘only identified by site’ or 
‘reverse’ were filtered, and the LFQ intensities transformed by 
log2. Experimental replicates were grouped, and two valid LFQ 
values were required in at least one experimental group. Missing 
values were imputed using default settings, and the data distribu-
tion visually inspected to ensure that a normal distribution was 
maintained. Statistically significant competition was determined 
through the application of P2 tests, using a permutation-based 
FDR of 0.05 and an S0 of 2, and data were visualized in volcano 
plots. 
The accompanying SI Data Excel file contains a summary of 
the chemoproteomic data. 
Transcriptional responses to SPIN1 inhibitor and siRNA 
knockdown in squamous cell carcinoma cell lines 
SSC040 cells were seeded into wells of a 48-well plate at a 
density of 10,000 cells/well in DMEM medium (supplemented 
with 10% FCS,  2 mM L-Glutamine, 100 units/mL penicillin, 100 
ug/mL streptomycin, 1x NEAA). Compounds (35 and 38 or 
DMSO control) or siRNA were added 24 hours later. RNA was 
harvested using Trizol reagent, 2 and 4 days after addition of 
siRNA, or 5 and 7 days after addition of compounds. RNA was 
purified using a Direct-zol RNA miniprep kit (Zymo Research). 
Experiments were conducted in 2 biological replicates, with n=3 
technical replicates per condition. 
RNAseq, library preparation, sequencing 
 
RNA concentration derived from inhibitor experiments (n=3, 
technical replicates) was normalized to 100 ng/50 uL and Illumina 
libraries were prepared using a NEBNext Poly(A) mRNA Mag-
netic Isolation Module in conjunction with a NEBNext Ultra II 
Directional RNA Library Prep Kit (New England Biolabs), ac-
cording to the manufacturer’s instructions. Libraries were quanti-
tated using the Agilent High Sensitivity D1000 ScreenTape Sys-
tem on a 2200 Tapestation (Agilent), pooled at equimolar concen-
tration, denatured and sequenced on a NextSeq 500 platform (Il-
lumina). 
NGS data processing and analysis 
Sequencing reads from the RNAseq experiment were aligned to 
the human genome (hg38) using HISAT73 with default parame-
ters. The program featureCounts74 was used to assign mapped 
reads to genes with annotation (gtf file Ensembl87). Differential 
gene expression analysis was performed using DESeq275 with an 
FDR-adjusted p value < 0.05 and log2 fold change >1. Functional 
analysis of differentially expressed genes was performed using 
Reactome.76 
Statistical methods and data analysis 
All statistical analyses and data fitting were performed using 
GraphPad Prism software version 7. Data were analyzed using 
two-sided t tests or one-way ANOVA, unless otherwise stated, 
and as indicated in the figure legends with a p-value < 0.05. Sta-
tistical analysis of the sequencing data, data collection and struc-
ture refinement was automatically performed in all of the pro-
grams used as noted above. The number of sampled units (n) as 
well as the number of technical replicates is indicated in the figure 
legends. 
The accompanying SI Data Excel file contains the RNAseq da-
ta. 
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